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1H Ȯ Proton (magnetic nuclei - 100% natural abundance) 
15N Ȯ Nitrogen isotope-15 (magnetic nuclei Ȯ 0.36% natural abundance) 
2D Ȯ Two dimensional 
3D Ȯ Three dimensional 
Amp Ȯ Ampicillin 
AMPS Ȯ Ammonium perulphate 
Chloramp Ȯ Chloramphenicol 
D2O Ȯ Deuterium oxide 
Da Ȯ Dalton 
DTT Ȯ Dithiothreitol 
E. coli Ȯ Escherichia coli 
EDTA - ethylenediaminetetraacetic acid 
ER Ȯ Endoplasmic Reticulum  
ERo1 Ȯ Endoplasmic reticulum protein oxidoreductin-1 
GB1 Ȯ B1 domain of the Streptococcus protein GB1 
hPDI Ȯ human Protein Disulphide Isomerase  
HSQC Ȯ Heteronuclear Single Quantum Coherence 
IPTG - Isopropyl ‚?-D-1-thiogalactopyranoside 
LB Ȯ Lysogeny Broth 
NMR Ȯ Nuclear Magnetic Resonance 
PDI Ȯ Protein Disulphide Isomerase 
Ppm Ȯ Parts per million 
P+ Ȯ Precision plus marker (Bio-rad) 
Rpm Ȯ Revolutions per minute 
SDS Ȯ Sodium dodecyl sulfate 
SDS-PAGE Ȯ Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
TEMED - Tetramethylethylenediamine 
TGS Ȯ Tris-glycine SDS buffer 
UPR Ȯ Unfolded Protein Response 




Protein Disulphide Isomerase (PDI) is a 57 kDa multi-domain protein found within 
the endoplasmic reticulum. PDI consists of four thioredoxin-like domains (named a 
and b) ȱ ȱ ȱ ‚?-ȱ ȱ ȱ ‚?-helices in the conformation 
‚?‚?‚?‚?‚?‚?‚?‚?‚?ǯȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱȂxȂc; with a 19 
amino acid x linker between the Ȃ and Ȃ domains, and an acidic tail, c, after the Ȃ 
domain. PDI acts as an oxidoreductase and chaperone to help fold newly 
synthesized proteins into their native state through the formation of disulphide 
bonds via the oxidation of sulfhydryl groups of cysteines, as well as the 
rearrangement of mispaired disulphides in an isomerisation reaction. The catalytic 
domains responsible for the thiol/disulphide reactions are a and Ȃ, and one of the 
aims of this work is to determine the redox potential of the Ȃ domain and how it is 
influenced by the adjacent Ȃ, x and c regions. Fragments of human PDI containing 
the Ȃ domain were expressed in E.coli and their redox potential measured by 15N/1H 
NMR using mixtures of reduced and oxidised glutathione. The Ȃ domain of PDI 
which is known to contain the primary binding site for unfolded substrates was also 
investigated. The interaction of the Ȃ¡Ȃ ȱȱȱȱȱ‚E-somatostatin 
fused to the carrier protein GB1 was used to investigate its binding behaviour by 











The endoplasmic reticulum (ER), located in all eukaryotic cells, has a vast array of functions; 
one of its key functions being; acting as the cells centre for protein folding and quality 
control [1]. This is essential; as even though the proteins final conformation is determined by 
its amino acid sequence the ER plays a large part in increasing the efficiency of folding the 
proteins into their final structure [2].  
As proteins are folded into their final form, post-translational modifications such as 
disulphide bonds are formed as part of the folding process, these bonds are produced via 
reduction-oxidation (redox) reactions.  This bond is formed when two side chain cysteine 
residues are oxidised to form a covalent sulphur-sulphur bond, this reaction is catalysed by 
one of the many resident molecular chaperone and protein folding catalysts located in the 
ER such as Protein Disulphide Isomerase (PDI) [3]; a protein expressed in nearly all 
mammalian tissues [4].  
[2] 
 
The discovery of this protein was made in 1963 by two independent research groups, first by 
Venetianer and Straub by extracting PDI from chicken and pigeon pancreas [5], and 
secondly by Goldberger, Epstein and Anfinsen from purified rat liver samples [6]. This 
makes PDI the founding member of the PDI family of thiol-disulphide oxidoreductases. 
This introduction focuses on the structure and function of the human PDI (hPDI) family, and 
goes into detail on the structure-function relationship in relation to redox reactions and 
chaperone activity. 
1.2 Introduction to PDI 
PDI is one of a family of 21 structurally related proteins (shown in Figure 1.1); grouped 
together due to their thioredoxin-like domain structure and although the family name of 
PDI implies that all the proteins within the family possess isomerase activity (redox reaction 
with no net change in charge) this has not been demonstrated experimentally for all of them. 
PDILT also lacks any obvious oxidoreductase activity [7], which is probably true of the PDI 
family members ERp44, AGR2 and AGR3 as well; as they also only have one cysteine in the 
active site [8]. ERp27 and ERp29 are also non-catalytic members of the PDI family [9]; 
showing that the grouping of these proteins into the PDI family is based largely on 










Figure 1.1 The 21 members of the PDI family of proteins 
The catalytic domains of a and Ȃ being shown in blue, the non-catalytic domains b and 
Ȃ shown in green and purple respectively, the x linker between Ȃ and Ȃ shown in 
orange and the transmembrane domains shown in red. 
Adapted from Andreu et al 2012 [36]. 
[4] 
 
        10         20         30         40         50         60  
DAPEEEDHVL VLRKSNFAEA LAAHKYLLVE FYAPWCGHCK ALAPEYAKAA GKLKAEGSEI  
 
        70         80         90        100        110        120  
RLAKVDATEE SDLAQQYGVR GYPTIKFFRN GDTASPKEYT AGREADDIVN WLKKRTGPAA  
 
       130        140        150        160        170        180  
TTLPDGAAAE SLVESSEVAV IGFFKDVESD SAKQFLQAAE AIDDIPFGIT SNSDVFSKYQ  
 
       190        200        210        220        230        240  
LDKDGVVLFK KFDEGRNNFE GEVTKENLLD FIKHNQLPLV IEFTEQTAPK IFGGEIKTHI  
 
       250        260        270        280        290        300  
LLFLPKSVSD YDGKLSNFKT AAESFKGKIL FIFIDSDHTD NQRILEFFGL KKEECPAVRL  
 
       310        320        330        340        350        360  
ITLEEEMTKY KPESEELTAE RITEFCHRFL EGKIKPHLMS QELPEDWDKQ PV KVLVGKNF  
 
       370        380        390        400        410        420  
EDVAFDEKKN VFVEFYAPWC GHCKQLAPIW DKLGETYKDH ENIVIAKMDS TANEVEAVKV  
 
       430        440        450        460        470        480  
HSFPTLKFFP ASADRTVIDY NGERTLDGFK KFLESGGQDG AGDDDDLEDL EEAEEPDMEE  
 
       490  
DDDQKAVKDE L  
 
Figure 1.2 Full amino acid sequence of hPDI 
a domain is shown in red, b domain in orange, Ȃ domain in green, the x linker in purple, 
the Ȃȱ domain in blue and the c-terminal tail in black, both CGHC catalytic sites are 
highlighted in yellow. 
Domain boundaries defined by Alanen et al 2003 [27]. 
 
PDI is a 491 amino acid, 57kDa protein, the full amino acid sequence of which is shown in 
Figure 1.2. As well as acting as an independent entity PDI also forms the ‚?-subunit of prolyl 
4-hydroxylase [10], involved in synthesis of collagen [11], and the 58 kDa subunit of 
microsomal triglyceride transfer protein complex involved in lipoprotein assembly [12].  
 
 
As well as catalysing the formation of disulphide bonds; PDI can also form a PDI-substrate 
complex [13], can interact with polypeptides which are prone to aggregation [14], in 




When PDI has a peptide bound to it; it can help to stabilise the major histocompatibility 
complex (MHC) class I within the ER by regulating disassociation of tapasin-ERp57 
disulphide conjugate by binding to both tapasin and ERp57 causing them to dissociate from 
one another. On the other hand when PDI does not have a peptide bound to it, it cannot 
dissociate the tapasin-ERp57 conjugate, resulting in MHC class 1 being retained in the ER 
[16].  
Another function was suggested for PDI relatively recently, the ability for it to act as a 
reservoir for hormones, this is due to the observation that hormone 17‚?-estradiol was able to 
bind to the hydrophobic region between the b and Ȃ domains. It was shown that the amino 
acid residue H256 was the key residue for the interaction between PDI and 17‚?-estradiol, 
and it is believed that the nitrogen of H256 is linked via a hydrogen bond to the 3-hydroxyl 
group of the hormone [17]. 
Ȃȱ ȱ ¢ȱ ȱ he efficient folding of newly translated proteins into their 
native state in the ER is essential, as potential disease states can occur due to aggregation of 
these proteinsǰȱȱȱȱǰȱǰȱ£ȂȱǰȱȂȱȱȱ
both non-alcoholic and alcoholic liver disease [18]. 
Although PDI is mainly located within the ER; it has also been found in other places such as 
the cell membrane [19], where it has been shown to aid in the fusion of the HIV envelope 
(Env) glycoprotein (gp) 120 to the lymphocyte receptors CD4 and CXCR4 of the CD4(+) 
lymphocytes. PDI aids in the fusion of HIV to the cell membrane by catalysing thiol-
[6] 
 
disulphide interchange reactions on the cell membrane; altering gp120 via the reduction of 
two disulphide bonds and allowing the HIV to fuse [20], [21].   
On the cell surface; PDI is also thought to play a regulatory role in the proliferation, 
adhesion, aggregation and secretion of platelets by reducing the disulphide bonds on 
fibrinogen receptors in platelets, this exposes them and activates the glycoprotein IIbIIIa 
receptor [22].  
PDI can be transported into the cytosol where it can eventually be presented on the cell 
surface exhibiting immunogenic characteristics, as they can appear as damage associated 
molecular patterns which the immune system targets to induce apoptosis [23]. 
All of this coupled with the fact that over a third of all human proteins that are secreted 
contain disulphide bonds [24] and that PDI (the most abundant member of its family) makes 
up roughly 0.8% of total cell protein within the ER lumen  [25]; makes PDI a very interesting 
target for research. 
 
1.3 Structure of hPDI 
Ȃs structure consists of four thioredoxin-like domains each containing five ‚?-sheets and 
four ‚?-helices in the conformation ‚?‚?‚?‚?‚?‚?‚?‚?‚? [26]. The four domains are thioredoxin-like 
as they are similar in structure to the protein thioredoxin as they share the same thioredoxin-
like structural fold of ‚?‚?‚?‚?‚?‚?‚?‚?‚?ȱ[26]. 
[7] 
 
Figure 1.3 Full PDI domain structure.  
Catalytically active domains shown in green, the catalytically inactive domains b and Ȃ 
represented in orange and red respectively, the x linker responsible for the U shape 
structure of PDI in white, acidic tail c in yellow and the KDEL endoplasmic reticulum 
retention sequence after the C-terminal.  
Adapted from Parakh, S. and Atkin, J.D. (2015) [116]. 
The four domains are ordered in the sequence ȂȂ; with a 19 amino acid x linker between 
the Ȃ and Ȃ domains, and an acidic tail, c, after the Ȃ domain, this makes the final sequence 
Ȃ¡Ȃ, demonstrated in Figure 1.3 below. The acidic tail c contains a KDEL retention 
sequence which keeps PDI within the ER. The b and Ȃ domains do not contain a catalytic 
active site whereas the a and Ȃ domains both contain CXXC active site motifs  [27], [28]. 
These 4 domains are arranged in a U shape with both catalytic domains a and Ȃ at the top 
and the non-catalytic domains b and Ȃ at the bottom (see Figure 1.4) [29]. 
The structure of PDI (Figure 1.4) has been developed relatively recently through the study of 
several PDI family members leading to insights into the structure and mechanisms by which 
the proteins function. Although the biggest advanȱ ȱ ȱ ȱ ȱ Ȃȱ
ȱ ȱ ȱ ¢ȱ ŗȂȱ -length crystal structure was solved, implying the 
position of substrates relative to the two catalytic domains [29]. The first near full length 
crystal structures of hPDI Ȃ¡Ȃ in both the oxidised and reduced states was recently 
published in 2013 [30] along with the Ȃ¡Ȃ hPDI in 2012, both studies suggested that the 
removal of the acidic c tail of PDI helps the crystallisation process [31].  
[8] 
 
Figure 1.4 Full structure of PDI 
Section A - The ribbon structure of PDI with the a domain in purple, b domain in 
turquoise, the Ȃ domain in yellow, the x linker indicated by the letter x, the Ȃ domain in 
red and the c-terminal tail in green. The catalytic active sites in the a and Ȃȱdomains are 
represented by the grey and yellow balls, the sulphur atoms being represented in yellow. 
Section B Ȯ A structural comparison of the four main domains of PDI. All four domains 
are shown in the same orientation with the alpha helices above and below the beta sheets 
in the middle 
Adapted from Tian, G., et al 2006 [29]. 
The Ȃȱdomain has been shown to act as the ligand binding domain to aid in the folding of 
peptide ligands as well as misfolded proteins whereas the a and Ȃ domains facilitate the 
catalytic oxidase and reductase activity due to their CXXC active site motifs or to be specific 
WCGHC [32]. The Ȃ domain is essential for the isomerase activity of PDI to take place as the 
minimum PDI fragment for the isomerase activity is Ȃ¡Ȃ, whereas for the redox reaction to 
take place the catalytic domains a and Ȃ can work in isolation [31]. 
The non-catalytic domains b and Ȃ contain lower sequence homology to thioredoxin than 
the catalytic domains a and Ȃ; this is true across all the PDI family; they also present an 
increased structural variability, such as the PDI family member ERp44 (ER protein, 44kDa), 




The b domain is thought to play a part  in protein solubility due to its overall hydrophilic 
properties [34], the b domain also has a higher than usual number of hydrophobic regions 
which assists in increasing the binding cleft between the catalytic domains therefore 
allowing larger peptides and misfolded peptides to bind [35].  
1.4 Catalytic Activity 
The catalytic activity of PDI involves the formation of disulphide bonds via the reduction, 
oxidation and isomerisation of disulphide bonds. The catalytic motif CXXC is essential for 
activity and found in all catalytically active domains. Other variants of the motif can also be 
found, but these domains are thought to be catalytically inactive [36]. PDI acts as a good 
oxidant due to its redox potential being -ŗŞŖǰȱ ȱ ȱ ȱȂȱȱȱȱ
unstable, making it easier for it to become reduced as it is more ready to accept electrons 
[37]. 
PDI catalyses the formation of disulphide bonds through the oxidation of sulfhydryl groups 
of cysteines, as well as the rearrangement of some mispaired disulphide bonds in an 
isomerisation reaction where there is no net change in charge [1] (shown in Figure 1.5). PDI 
catalyses the formation of these disulphide bonds as its oxidised a domain is able to catalyse 
the oxidation of a reduced substrate, therefore causing itself to become reduced. PDI 
substrates predominantly contain cysteine residues which are in the reduced dithiol state (R-
S-H) but are then oxidised to form disulphide bonds (R-S-S-R). In PDI, the cysteine residue 
on the N-terminus (C53) forms an intermediary disulphide bond with the substrate while 
the substrate is released by the C-terminus cysteine, C56 [38]. The a domain is then re-
oxidised by the Ȃ domain via an intramolecular reaction which allows the a domain to 
reform its disulphide bond [39]. The Ȃ domain is then re-oxidised itself by the ER 
[10] 
 
oxidoreductin protein ERo1 which involves the reduction of O2 to H2O2 [39], [40] 
(demonstrated in Figure 1.6). ERo1 is present in two isoforms ‚?ȱȱ‚?ȱthis is discussed in the 
next section [17]. 
Figure 1.5 Oxidoreductase and isomerisation activity of PDI 
For both figures, nucleophilic attack is shown by a solid curved arrow and the reverse 
reaction is shown by a dotted curved arrow 
Panel A Ȯ The formation of a disulphide bond on a substrate via the oxidisation of the 
substrate and the reduction of the N-terminal cysteine C53. In the intermediate step, the 
C-terminal cysteine of PDI must have a higher than average pKa value than the protein 
substrate, otherwise the reverse reaction will be kinetically more favourable. 
Panel B Ȯ The rearrangement of a mispaired disulphide bond on a protein substrate via 
an isomerisation reaction, again the intermediate step is shown. For reaction 1 to occur 
the N-terminal active site cysteine must have a low pKa value. In the intermediate 
reaction the C-terminal cysteine, C56, must have a higher than average pKa value, 
leading to direct isomerisation. If direct isomerisation does not occur, cycles of oxidation 
and reduction take place until the correct conformation is achieved. Reactions 1 and 3 
show reduction of a substrate disulphide bond by PDI. 





Figure 1.6 Oxidative protein folding pathway, complete cycle. 
The transfer of electrons within the endoplasmic reticulum protein folding pathway 
which results in the formation of disulphide bonds to help fold newly synthesised 
proteins into their native state. When non-native disulphides are formed, reduced 
glutathione assists in reducing them so that they can form a native disulphide bond. This 
decreases the GSH to GSSG ratio, altering the redox environment in the ER. 
Adapted from Bhandary, B., et al. 2013 [66]. 
It has been reported that the catalytic activity of PDI family members is regulated by the 
arginine residue located close to the CXXC motif [41], [42]. The pKa value of the cysteine 
residues in the active site plays a large role in determining the physiological function of PDI. 
Increasing the pKa value of the C-terminal  cysteine prompts the oxidation of substrates, 
whereas it causes an inhibitory effect to occur on the re-oxidation of PDI. However, a low 
pKa is required for PDI to become re-oxidised and complete the catalytic cycle. This 
situation is solved by the arginine residues, arginine 120, found in the loop between ‚?5 and 
‚?4 of the catalytic site of the a domain and arginine 461 in the Ȃ domain. This residues side 
chain moves in and out of the active site locale, which has an indirect regulatory effect on 





ȱ  ȱ ȱ ȱ ȱ ŗ‚?ȱ ȱ ȱȂ ȱ ȱ ȱ ȱ ȱ ‚?ȱ ȱ ȱ
ŗ‚?ȱȱ ȱȱȱŗ‚?ȱȱȱȱȱȱ¢ȱȱȱȱȱȂ domain 
Adapted from Wang, L., et al. 2009 [117]. 
1.5 Re-oxidation of PDI 
Once PDI has oxidised its substrate, it must be re-oxidised itself to complete the catalytic 
cycle. This can be achieved in a number of ways, GSSG present in the cell can re-oxidise PDI, 
as well as, hydrogen peroxide, Ero1‚?ȱȱ‚?ǰȱ¡ȱȱ¡¡ȱ[43]. 
Although both Ero1‚?ȱȱ‚?ȱȱ-¡ȱǰȱȱ‚?ȱȱȱȱȱȱȱȱ
human cells [44], whereas Ero1‚?ȱȱȱȱȱȱȱȱ[45].  
The Ȃȱdomain of reduced PDI is bound to by the ‚?ȱȱȱŗ‚?ȱaided by the co-factor 
FAD [46] (shown in Figure 1.7). This interaction is between the aromatic residues W272 of 
Ero1‚?ȱȱŘŚŖǰȱŘŚşȱȱřŖŚȱȱǰȱȱȱȱ ȱ-covalent [46]. This means 
that Ero1‚?ȱis orientated so that the Ȃ domain of PDI is oxidised but the a domain was left 
alone [39], [46].  After Ero1‚?ȱȱ-oxidised the Ȃ ȱȱǰȱŗ‚?Ȃȱ ȱȱȱȱ
re-oxidised, ultimately leading to the production of H2O2 as the electrons are passed to O2, 
ŗ‚?Ȃȱinner active site disulphides are used to achieve this [44]. ȱ‚?ȱȱ‚?ȱȱȱ
Ero1 preferentially bind to the Ȃ domain of PDI and oxidise it [47], [48]. 
[13] 
 
ŗ‚?ȱ ¢ȱ ¢ȱȱ affinity to PDI was shown to be pH dependent, with 
improved catalytic activity and binding affinity at pH 7 and depleted activity at pH 7.5 and 
8 [39].  
Obviously the Ȃ ȱ Ȃȱȱ-¡ȱȱȱȂȱaided in the re-oxidation of 
the a domain of PDI by accepting electrons from it [39]. The re-oxidation of the a domain is 
modulated by three other proteins present in the ER, they are, glutathione peroxidase 7 
(GPx7), glutathione peroxidase 8 (GPx8) and peroxiredoxin 4 (Prx IV) [49], [50]. H2O2 is a by-
product produced when Ero1‚?ȱȱ-oxidised, a build-up in hydrogen peroxide could result 
in damage to the cell, therefore GPx7 and GPx8 help to remove the hydrogen peroxide by 
converting it back to oxygen. In doing so C57 and C86 of GPx7 are converted into sulfenic 
acid and disulphide respectively [49], [50]. 
1.6 Chaperone activity 
PDI was first proposed to act as a chaperone, as well as a protein folding catalyst in 1993 
[51]. It was suggested that PDI plays a role in preventing protein aggregation by binding to 
unfolded proteins [52]Ȯ[55], as well as interacting with proteins that have been newly 
synthesised [56], [57]. 
All PDI domains contribute to its ability to bind  to specific proteins for its chaperone 
activity [58], although when PDI is in its oxidised form it has greater chaperone activity than 
when it is reduced. This is due to the conformational changes that occur when the Ȃ domain 
is oxidised, causing it to move out of its compact conformation exposing the hydrophobic 
areas [31], [59]. This shows that the chaperone activity of PDI is redox regulated, where 
being in its oxidised state results in an open conformation allowing itself to bind to larger 
non-native proteins and closed in its reduced state [31], [59]. This was discovered only 
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relatively recently due to issues in obtaining the crystal structure of human PDI in both the 
reduced and oxidised forms. The crystal structure obtained allowed us to observe that in its 
reduced form the a and Ȃȱȱ ȱŘŝǯŜȱ#Ȃȱȱ ȱȱȱȱ¡ȱȱ¢ȱ
are 40.3 Å apart as the Ȃ domain is twisted 45 degrees around the x linker and away from 
the Ȃ domain. Therefore in the oxidised state there are more open hydrophobic areas and a 
larger cleft for substrates to bind to at the Ȃȱdomain [30]. This adds to the evidence that the 
chaperone activity of PDI is regulated by its redox status. 
The Ȃ domain acts as the primary hydrophobic binding site for peptides and is the site at 
which the x linker binds, meaning peptides have to compete with the x linker to bind to the 
site [60], [61]. This discovery added further evidence to the hypothesis that the x linker aids 
in modulating the Ȃȱbinding site. 
In 2014 it was shown that PDI can distinguish between fully folded, partially folded and 
unfolded substrates This was shown as the dissociation constant (Kd) for fully unfolded 
basic pancreatic trypsin inhibitor (BPTI) was shown to be 1.5 ‚gM, whereas in its partially 
unfolded state the Kd was about three times higher, and in the fully folded state; ten times 
higher. This led to the conclusion that PDI can distinguish between fully folded, partially 
folded and unfolded substrates, with a preference to binding to unfolded substrates more 
strongly [62]. 
Ȃȱ ȱ ¢ȱ ȱ ȱ een demonstrated in vivo by the study of folding, 
modification and assembly of type X collagen in semi-permeable cells. This role is related to 
Ȃȱ¢ȱ ȱȱȱ ȱ‚? subunit of prolyl 4-hydroxylase as it interacts transiently 
with type X collagen during helix formation, this reaction is not thiol dependent as a type X 
[15] 
 
polypeptide was shown to be able to fold into its native state and interact with PDI despite 
the polypeptide not containing any cysteine residues [63]. 
1.7 Disease states and potential drug targets 
Even though the ER retains a large reservoir of chaperones and folding proteins, both 
misfolded and unfolded proteins can still build up leading to a range of disease states such 
ȱ£ȂǰȱȂǰȱȱȱȱ ȱȱ
Ȃȱǯȱȱȱȱ
the unfolded protein response (UPR) is activated, this involves, up regulating expression of 
chaperone proteins, targeting misfolded as well as unfolded proteins to be degraded by the 
proteasome, and also reducing the rate at which new proteins are synthesised [64]. 
PDI is upregulated in the UPR leading to a reduction in misfolded and unfolded proteins 
within the ER. However extensive activation of the UPR can lead to disease states itself, such 
as multiple metabolic diseases such as, obesity, diabetes, renal disease, macular 
degeneration, liver disease and atherosclerosis [65], [66]. This makes PDI a potential drug 
target so to inhibit chronic activation of the UPR. 
A number of PDI inhibitors have been discovered in recent years such as Bacitracin which 
consists of a mixture of polypeptides. The analogs of bacitracin have been shown to be more 
inhibitory than bacitracin itself, they bind to the Ȃ domain but do not appear to inhibit the 
oxidative and isomerase activity [67], [68]. 
A derivative of propynoic acid carbamoyl methyl amids (PACMA), named PACMA31 has 
been shown to be an irreversible inhibitor of PDI as it forms a covalent bond with the active 
site cysteine. PACMA31 can potentially be used to target ovarian tumours, this was shown 
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in 2012 as it bound to the overexpressed PDI in the ovarian tumour cells inhibiting their 
growth and yet caused no harm to normal cells in the process [69]. 
There are many peptides which can inhibit the chaperone activity of PDI, such as 
ribostamycin, which inhibits the chaperone activity [70]. Qurcetin-1-rutinoside is an 
inhibitor of Ȃ reductase activity as well as being able to inhibit PDI mediated platelet 
aggregation, leading to the idea that it can be used as an antithrombic agent [71].  
1.8 Project Aims 
The aim of this project is to characterise the redox potential of ȱȂȱȂ domain by 
expressing and purifying ¡Ȃ, Ȃ¡Ȃ and Ȃ in 15N isotopically enriched media. This is to 
elucidate how the addition of neighbouring domains influences its redox potential. To 
elucidate the redox potential of the Ȃ domain, the various fragments of PDI will be put into 
a range of redox conditions using oxidised glutathione (GSH) and reduced glutathione 
(GSSG) and analysed by NMR spectroscopy. 
Another aim of the project is to further characterise ligand binding behaviour of hPDI using 
the Ȃ¡Ȃ fragment and the ligand ‚E-somatostatin. Both GB1 and GB1-‚E-somatostatin were 
expressed and purified in 15N isotopically enriched media, whereas Ȃ¡Ȃ was expressed in 
unlabelled minimal media. The binding behaviour of Ȃ¡Ȃ to the GB1-‚E-somatostatin 
fusion was characterised by NMR spectroscopy together with the effect of the oxidation 




2.0 Materials and Methods  
Fragments were expressed from pET-23b vectors transformed into E. coli strain BL21 DE3 
pLysS [72]. The fragments were expressed and purified first on a small scale in 100  ml of 
lysogeny broth (LB) media  and minimal media (MM), and then scaled up for large scale 
production. GB1 and GB1-‚E-somatostatin fusion were also expressed from pET23a in BL21 
DE3 pLysS cells and the proteins purified from cultures grown both in LB and minimal 
medium. 
2.1 Growth on agar plates 
Agar plates were made using 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl and 15 g/L 
agar. AȱȱȱȱȱȱȱȱŗŖŖȱ‚gȦȱȱřŚȱ‚gȦȱ
respectively. Agar plates were streaked with appropriate E. coli glycerol stock (PDI 
fragments ¡Ȃ, Ȃ¡Ȃ or Ȃ, or PDI ligand GB1-‚E-somatostatin as well as the control GB1) 
and left to incubate overnight at 37 °C. 
2.2 Growth in LB media 
LB media was prepared containing 10 g/L tryptone, 5 g/L yeast extract and 10 g/L NaCl, and 
the same antibiotic concentration as used for growth on agar plates (see above). LB media 
was then inoculated with a colony from an agar plate and incubated at 200 rpm, 37 °C until 
the absorbance at 600nm = 0.6 
2.3 Growth in 15N labelled minimal media 
Minimal medium was prepared using the components shown in Table 1.1 and cultures 




Stock Component Stock Solution   Volume 
1 - (15NH4)2SO4 (x50) - 30 g/L 20 ml 







3 - Na2SO4 (x1000) - 42.6g/L 1 ml 















5 - MgSO4 (x1000) - 246 g/L 1 ml 
6 - CaCl2 (x1000) - 44.1 g/L 1 ml 
7 - Biotin (x1000) - 1 g/L 1 ml 
8 - Thiamine (x1000) - 1 g/L 1 ml 
9 - 13C6H12O6 (x50) - 150 g/L 20 ml 
10 - MilliQ® water - - 845 ml 
11- Ampicillin (x100) - 100 g/L 1 ml 
12 - Chloramphenicol (x100) - 34 g/L 1 ml 
Table 1.1 MM stock solutions and appropriate concentrations.  
2, 3 and 4 were all autoclaved whereas all other stock solutions were filter sterilised using a 
0.2 µm single use syringe (Sartorius, Epsom, UK) and then added aseptically once 
autoclaved solutions had cooled.  
 
2.4 Recombinant expression in E. coli 
Starting with a 50 ml starter culture of MM. The culture was grown at 37 °C, shaken at 200 
rpm until the A600 is 1.0. Cells were spun down at 4000 rpm, 4 °C for 15 minutes, supernatant 
poured off and the pellet re-suspended in 3 ml of MM. The re-suspended pellet was used to 
inoculate 3 x 400 ml MM cultures, 1 ml in each. The large cultures were incubated at 37 °C, 
200 rpm until A600 = 0.6. 
The cultures were then induced using IPTG at 0.5 mM overnight for the PDI fragments, but 
just 3 hours for the PDI ligands, both sets of cultures incubated at 30°C. The cultures were 
spun down at 10,000 rpm, 4 °C for 10 minutes using a JA-10 rotor, the supernatant poured 
off and each 400 ml culture equivalent pellet re-suspended in 10 ml lysis buffer (50 mM 
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NaCl, 20 mM NaH2PO4, pH 7.3, 4 °C). The 3 x 10 ml re-suspended pellets were split into 2 x 
15 ml (2 x 600 ml equivalent cell pellet) and frozen at -20 °C. 
0.5 ml pre and post IPTG samples taken for SDS-PAGE analysis, spun down in a centrifuge 
for 1 minute at 13,000 rpm, supernatant poured off and the pellet frozen at -20 °C. 
2.5 Cell Lysis 
PDI Fragments: 
600 ml equivalent cell pellet was defrosted at room temperature, 3ŖŖȱ‚gȱȱ-100 (5% v/v 
stock in lysis buffer) added and the solution incubated for 20 min ȱȱǯȱŝśȱ‚gȱ
MgCl2 ǻŘȱǼȱȱŗśŖȱ‚gȱȱ ǻŘȱȦǼȱwere then added and the solution incubated at 
room temperature for a further 20 min. The mixture was then centrifuged at 12,000 rpm, 4 
°C for 10 min (JA-20 rotor) and the supernatant collected for further protein purification. 
PDI Ligand: 
600 ml equivalent cell pellet defrosted at room temperature, lysis buffer added to a total 
ȱ ȱ ŘŖȱȱ ȱ ȱ ŚŖŖȱ‚gȱ ȱX-100 (5% v/v stock in lysis buffer) added. The 
mixture was sonicated in an ice bath for 3 min (10 s on / 10 s off); and the lysate then 
centrifuged at 4,000 rpm, 4 °C for 10 min (JA-20 rotor). The supernatant was collected for 
further protein purification. 
2.6 Nickel Affinity Chromatography 
A 2 ml and 5 ml bed volume column was used for the small and large preps respectively. 
Each column was packed with chelating sepharose fast flow (GE Healthcare). 
The column washed using 10 column volumes (CV) of MilliQ® water, charged using 1 CV of 
NiSO4 (0.2 M) in water, then washed with 5 CV sodium acetate (20mM sodium acetate, 0.5 
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M NaCl, pH 4) followed by 10 CV of binding buffer (20mM phosphate, 0.5 M NaCl, pH 7.3) 
to equilibrate it. 
The supernatant from the lysis was then loaded after it had been filter sterilised through a 
0.2 µm single use syringe (Sartorius, Epsom, UK), added to the column and 2 ml fractions of 
the flow through collected there on after. 10 CV of binding buffer was added to the column, 
then 10 CV of wash buffer (20 mM phosphate, 0.5 M NaCl, 50 mM Imidazole, pH 7.3), after 
which 15 CV of elution buffer (20 mM phosphate, 0.5 M NaCl, 20 mM EDTA, pH 7.3) was 
added to ensure elution of the protein. Ice cold binding, wash and elution buffer is used for 
PDI ligand purification. 
The fractions collected were kept for SDS-PAGE analysis and to measure their absorbance at 
280 nm to track the protein as it comes off the column. The column was stored in 20% 
ethanol at 4 °C. 
2.7 Dialysis 
Fractions were pooled and dialysed overnight at 4 °C against 2 l of 20 mM phosphate buffer, 
pH 7.3 (MWCO 12-14 kDa). 
2.8 Ion Exchange Chromatography 
Ion exchange chromatography was used to further purify the PDI fragments. An AKTA 
FPLC analyser (GE Healthcare) was used with a Source 30Q column (5 ml bed volume), with 
Buffers A and B (20 mM phosphate, pH 7.3 and 20 mM phosphate, 0.5 M NaCl, pH 7.3 
respectively). The buffers were filtered and degassed before use. 
[21] 
 
The column was first washed using 10 CV of buffer A, followed by 10 CV of buffer B and 
then equilibrated using 10 CV buffer A. A blank gradient of buffer B (0 to 100% over 10 CV) 
was run to elute any contaminants on the column before use.  
The dialysed protein was loaded onto the column using a 10 ml superloop and the 
separation of bound protein achieved using 0 to 100% of buffer B over 20 CV at a flow rate of 
5 ml/min. 2 ml fractions were collected and their absorbance measured at 280 nm. Fractions 
were analysed by SDS-PAGE. 
2.9 Gel Filtration 
ȱȱȱȱȂ¡Ȃǰȱȱȱ ȱ after ion exchange chromatography 
to separate the monomer and dimer forms. Superdex 200 matrix (300 ml; GE Healthcare) in a 
XK 26 column (2.6 cm diameter) was used with 20 mM phosphate buffer containing 0.15 M 
NaCl (pH 7.3) as running buffer. The pooled ion exchange samples were spin concentrated 
to 2 ml using a 10,000 MWCO Vivaspin 20 concentrator before loading. The column was run 
at a flow rate of 2 ml/min and 5 ml fractions were collected. The absorbance of each fraction 
was measured at 280 nm. 
2.10 SDS-PAGE 
The protein was analysed at each purification step using sodium dodecyl sulphate gel 
electrophoresis (SDS-PAGE). Table 1.2 below shows solutions for both the resolving and 
stacking gels. The protein standard used was Precision Plus from Bio-Rad. TGS buffer 5 x 
stock was made using glycine 0.95 M (pH 8.3), 0.125 M Tris and 0.5% SDS. 4 x non-reducing 
loading was prepared with 0.33 M Tris-HCl, 8% SDS, 0.4% bromophenol blue and glycerol, 
final concentration was 40% in Sambrook & Russell 2001. For the reducing buffer 200 mM 
DTT was used and then stored at -20 °C. 
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Table 1.2 Components of 15% and 17.5% SDS-PAGE resolving gel and 5% stacking gel 
PDI fragments analysed using 15% resolving and PDI ligands analysed using 17.5% 
resolving gels. 
ŗŖȱ‚gȱȱȱŚ¡ȱȱȱ ȱȱȱřŖȱ‚gȱȱȱȱȱȱȱȱȱŚŖȱ‚gȱ
with a 1x reducing buffer, SDS-PAGE samples were then placed in boiling water for 3 
ǯȱ ŗŖȱ ‚gȱsamples were placed in each well. Gels were run at 100 V through the 
stacking gel and 125 V through the resolving gel. Gels were stained using Coommassie stain  
containing 1 mg/ml Coommassie Brilliant Blue Bio-Rad, 10% acetic acid, 40% methanol and 
50% MilliQ® water. Gels were stained for 3 hours and then de-stained with a solution 
containing 10% acetic acid, 10% methanol and 80% water. 
2.11 Mass Spectrometry 
Electrospray mass spectrometry was used to elucidate the molecular mass of purified 
proteins. All analyses were carried out by Kevin Howland (biomolecular science facility, 
Kent) using a Waters Synapt G2-Si mass spectrometer. The samples were desalted on-line by 
reverse-phase HPLC on Phenomonex Jupiter C4 column (5 µm, 300$, 2.0 mm x 50 mm) 
running on a Waters H Class Acquity UPLC system at a flow rate of 0.2 ml/min using a short 
water, acetonitrile, 0.1% formic acid gradient. The eluent was monitored at 280 nm and then 
directed into the electrospray source, operating in positive ion mode and mass spectra 
Reagent 15% Resolving Gel 17.5% Resolving Gel 5% Stacking Gel 
40 % Acrylamide 7.5 ml 8.75 ml 1.25ml 
1.5 M Tris pH 8.8 5 ml 5 ml - 
0.5 M Tris pH 6.8 - - 1.25ml 
10% SDS ŘŖŖ‚g ŘŖŖ‚g ŗŖŖ‚g 
MilliQ® water 7.1 ml 6.85 ml 7.3ml 
10% AMPS śŖȱ‚g śŖȱ‚g śŖ‚g 
TEMED ŗŚȱ‚g ŗŚȱ‚g ŗŖ‚g 
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recorded from 500-5000 m/z.  Data was analysed and deconvoluted to give uncharged 
protein masses with Waters UNIFI software and the MaxEnt 1 algorithm. 
2.12 Determination of protein concentration 
Absorbance of the pooled PDI fragment samples were measured at 280 nm after ion 
exchange chromatography using an Ultropsec 2000 UV/Visible Spectrophotometer 
(Pharmacia Biotech). For the PDI ligand the A280 was measured after nickel column 
chromatography. The extinction coefficients were calculated from the amino acid sequence 
using ProtParam on the EXPASy website (http://web.expasy.org/protparam/). 
2.13 Concentrating the protein 
Pooled protein samples were concentrated using ultrafiltration. 10,000 Da MWCO Vivaspin® 
20 spin concentrators were used for the PDI fragments and 5,0000 Da MWCO Vivaspin® 4 
spin concentrators used for the PDI ligand. The concentrators were operated at 2000 rcf 
(bench centrifuge), 4 °C. Proteins were typically concentrated to 0.5 mM, aliquoted and 
frozen at -80 °C until needed. However, Ȃ¡Ȃ was kept at 4 °C and used as soon as possible. 
2.14 NMR Sample Preparation 
řȱȱȱȱ ȱȱ ȱȱȱȱȱŘśŖȱ‚gǯȱŗŖȱƖȱ2ȱǻŘśȱ‚gǼǰȱŖǯŗśȱȱȱ
ȱǻŝśȱ‚gǼȱȱȱȱȱȱśȱȱ	
Ȧ		ȱ as used for ¡Ȃȱand Ȃ¡Ȃ, 
and rDTT/oxDTT was also used for Ȃ but to a total concentration of 1.5 mM. 
2.15 NMR Data acquisition and processing 
Heteronuclear single quantum coherence (HSQC) was the NMR experiment utilised 
throughout the study, all experiments were run at 298 K. 15N HSQC spectra were obtained 
with 256 points in the F1 dimension (15N) and 2048 points in the F2 dimension (1H). The 
[24] 
 
NMR data was acquired and processed with the assistance of Dr Mark Howard and Dr 
Haris Panagos using NMRpipe. The spectrometer used to acquire the data was a Bruker 
AV3 (Avance III) 600 MHz operating a 5 mm QCI-F cryoprobe.  
For the ligand binding experiments, minimal chemical shift mapping was used. The data 














To produce large quantities of 15N labelled PDI fragments and ligands for NMR 
experiments; recombinant expression in E. coli was used. This technique can produce large 
quantities of protein quickly and cheaply, as well as allowing for easy isotopic enrichment of 
over 95% with 15N. The T7 polymerase-based pET system was used to express the proteins 
using the E. coli strain BL21 (DE3) pLysS. This recombinant expression system utilises the 
lacUV5 promoter regulated T7 RNA polymerase gene [74], [75].                  
This system is one of the most popular and effective expression systems to use due to the T7 
RNA polymerases high level of activity leading to more than 50% of the total cell protein 
being the desired recombinant protein after the lacUV5 promoter is induced with isopropyl-
‚?-D-thiogalactopyranoside (IPTG) [74]. IPTG is an effective inducer as it is not degraded by 
components of the cell and it imitates the natural inducer of the lac operon, lactose, the only 
down side is that it is both expensive and toxic [75]. 
[26] 
 
IPTG works by binding to the inhibitor of the lac operator, Lacl, this prevents Lacl from 
inhibiting the lac operator which regulates the lacUV5 promoter as well as the T7-lac hybrid 
promoter (shown in Figure 2.1). Lacl is bound to by a water molecule coupled with IPTG via 
hydrogen bonds and a IPTG hydroxyl group at S193 and D149, this prompts the lac operator 
inhibitor to undergo a conformational change where it moves away from the lac operator, 
allowing transcription to occur [76]Ȯ[78]. 
 
BL21 cells contain the pLysS plasmid which provides chloramphenicol resistance as well as 
coding for the T7 lysoszyme which aids in reducing background expression and improving 
the stability of the plasmid. BL21 cells are lacking the proteases OmpT and Lon which helps 
to reduce contamination of purified recombinant proteins by preventing the heat shock 
protein Hsp70 from being produced. As Hsp70 accounts for 1% of the total protein found in 
E. coli, this helps in producing the highest purity of the recombinant protein with the fewest 
number of purification steps [79], [80]. 
A. B. 
Figure 2.1  
Binding mechanism (A) and structure (B) of IPTG. IPTG shown in green, water molecule 
in black, Lacl as red and turquoise and the lac operator as blue.  




The pET-23a(+) vector shown in Figure 2.2 was used for the GB1 and GB1-‚E-somatostatin 
constructs, whereas for the PDI fragments the vector pET-23b(+) was used [74]. 
 
The amino acid sequences of both PDI fragments and ligands are shown below.  











Figure 2.2 pET23a(+)  








His-tag shown in green, Ȃ domain in red, x linker in grey, Ȃ domain in blue and the tail c in 
black, the Ȃ active site is highlighted in yellow. 
PDI domains defined by Alanen et al. 2003 [27]. 
Sequences of PDI ligands: 





GB1 and GB1-‚E-som. with the FXa cleavage site between GB1 and ‚E-som. 
Double His-tag shown in blue, GB1 in black, FXa cleavage site in green and ‚E-som. in red 
 
1.2 Protein expression and purification 
NMR experiments require the protein samples to have a high percentage of 15N to produce 
high quality data however naturally occurring 15N is only present in very low quantities at 
0.23%. Therefore both the PDI fragments and ligands were grown in minimal media 
containing 15N ammonium sulphate; this meant that the only nitrogen source was the 
ammonium sulphate allowing for a high percentage of the protein to be isotopically labelled.  
For the PDI ligand experiments, unlabelled Ȃ¡Ȃ is required, the PDI construct was still 
grown in MM though. This was to try and prevent dimerization, as it has been previously 
reported that more dimerization occurs when Ȃ¡Ȃ is recombinantly expressed in LB media 
[81]. This could be due to it being expressed at a faster rate in LB media leading to a closer 
proximity of unfolded protein meaning greater dimerization occurs.  
[29] 
 
Throughout the purification process SDS-PAGE analysis was carried out to help ensure that 
the protein was being purified and was still present. Mass spectrometry was also utilised to 
make sure that the final product was the desired protein. 
Firstly to release the proteins from the induced E. coli cells, the cells had to be lysed. The E. 
coli cells contained the cell wall disrupting protein T7 lysozyme due to the pLysS plasmid, 
therefore the freeze thaw process was utilised to lyse the cells.  
Nickel affinity chromatography was used due to the His-tag located at the N-terminus on 
each of the PDI fragments and ligands. This allowed the protein to bind tightly to the nickel 
in the column as the unwanted protein was washed off. Firstly nickel was added to the 
column so it could bind to the chelating sepharose beads. After which the impure protein 
was added and then washed, first with binding buffer to wash off any very loosely bound 
protein, followed by a wash buffer containing imidazole. The imidazole washes off the 
weakly bound protein, leaving the His-tagged protein still bound to the nickel. Finally 
elution buffer was used to elute the protein from the column, this contained EDTA which 
strips the nickel off the column meaning the protein is washed out too. After dialysis to 
remove the nickel from the protein, the PDI fragments were further purified using ion 
exchange chromatography; this used the theoretical isoelectric point (pI) of the protein to 
separate out the impurities. Theoretical pI values are shown below in Figure 2.3 and were 
acquired by entering the amino acid sequences into ProtParam on the ExPASy website 
(http://web.expasy.org/protparam/). The negatively charged protein binds to the positively 








Figure 2.3 Theoretical pI for PDI fragments 
As previously mentioned Ȃ¡Ȃ requires a further purification step to separate out the 
monomer from the dimer, gel filtration chromatography was used for this. The Ȃ¡Ȃȱ








2.1 PDI Fragments 
2.1.1 Expression 
To show that the induction of the cells to produce the desired protein was successful, SDS-
PAGE analysis was carried out on culture samples before and after induction. Figure 2.4 
shows SDS-PAGE analysis of Ȃ¡Ȃ expression for two separate culture growths. The ¡Ȃ 
band is seen at expected molecular mass of 32 kDa. 
This shows a typical stage of analysis for pre and post IPTG used for the PDI fragments. 




















































































Figure 2.4 SDS-PAGE analysiȱȱȂ¡Ȃȱ¡ 
Precision plus marker is shown on the left and right hand sides of the pre and post IPTG 
sample lanes. Ȃ¡Ȃȱ is indicated by the arrow. All lanes were in reducing conditions 
using DTT. Lanes 1, 2, 9 and 10 contain 1x Sample Buffer, lanes 3 and 8 contain precision 
plus marker, lanes 4 and 6 contain pre-IPTG samples from two different cultures and 
lanes 5 and 7 contain post-IPTG samples from two different cultures. 
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16 kDa respectively. This made SDS-PAGE analysis at each stage of the purification 
procedure an invaluable tool. 
 
2.1.2 Purification 
2.1.2.1 Nickel Affinity Chromatography 
Nickel affinity chromatography was utilised for all the PDI fragments and proved to be 
effective in removing the vast majority of the unwanted protein present in the supernatant. 
SDS-PAGE analysis of Ȃ¡Ȃ during cell lysis, loading and running of the nickel affinity 
column is shown in Figure 2.6. The total lysis sample was taken just before the lysate was 
spun down, the supernatant sample was taken post centrifugation, the pellet sample was 
taken after the pellet was re-suspended in an equivalent amount of lysis buffer, and the flow 
through was taken after the supernatant had gone through the column. The fractions shown 
after the flow through were samples taken once the elution buffer had been added, across 
the elution buffer peak as shown below. ¡Ȃ and Ȃ were purified and analysed in the same 
way. 
Figure 2.5 shows the buffers used and the run off from the column. Binding buffer was used 
to wash off the protein that was not bound to the column; the wash buffer (50 mM 
imidazole) was then added to wash off any protein which is weakly bound to the column. 
The desired protein should remain bound to the nickel column due to the His-tag which 
binds to the nickel, the protein is only washed out once elution buffer (20 mM EDTA) is 



























































































Figure 2.6 SDS-PAGE analysis of nickel affinity chromatography 
The elution samples are labelled with fraction number as shown in Figure 2.5. Ȃ¡Ȃ is 
indicated by the arrow. All lanes were in reducing conditions using DTT. Lane 1 contains 
precision plus marker, lane 2 contains a sample of total lysate, lane 3 supernatant, lane 4 
cell pellet, lane 5 flow through, lane 6 fraction 33, lanes 7 Ȯ 10 fractions 67 Ȯ 70, lane 11 
fraction 72 and lane 12 fraction 74.  
Figure 2.5 Nickel affinity chromatography of Ȃ¡Ȃ 
The absorbance at 280nm of the samples is shown, B is when the binding buffer is added, W 
is when the wash buffer was added and E is when the elution buffer was added. The black 



































The lysis of the cells may not have been complete due to the presence of some Ȃ¡Ȃ in the 
pellet sample, this was also seen for both ¡Ȃ and Ȃ.  
For all three PDI fragments; the vast majority of the impurities were removed through the 
use of nickel column chromatography, but some impurities still remained. Ion exchange 
chromatography was used to further purify the protein once the peak fractions were pooled 
and dialysed to remove the high salt concentration. This made it necessary to utilise another 
purification step once the fractions containing the protein had been pooled and dialysed to 
remove the nickel. 
2.1.2.2. Ion Exchange Chromatography 
As this is the final purification step for ¡Ȃ and Ȃ, their SDS-	Ȃȱ ȱ ȱ  ǯ 
Figure 2.7 below shows the peak of Ȃ¡Ȃ with contaminants eluting after the main Ȃ¡Ȃ 
peak. It has been previously reported [81]; that even when the ion exchange peak appears 
symmetrical, implying only the presence of one species of the protein being present, native 
PAGE analysis showed this to be wrong, as at least two forms of the protein were present. 








Figure 2.7 Ion Exchange Chromatography of Ȃ¡Ȃȱ a 5ml Source30Q column 
The absorbance at 280nm is shown by the blue line, while the conductivity is shown 























































Elution Volume (ml) 
 
The SDS-PAGE analysis (Figure 2.8) showed the high level of purity achieved for Ȃ¡Ȃ 
from ion exchange chromatography.  A minor contaminating band at 250 kDa could be seen, 








MW (kDa)   M         1          2          3           4         5          6          7         8           9          10          11 
Ȃ¡Ȃ 
Figure 2.8 SDS-	ȱ¢ȱȱȂ¡Ȃȱȱȱ¡ȱ¢ 
M is the precision plus marker, Lanes 1 Ȯ 11 contain ion exchange fractions taken across 
the peak. Ȃ¡Ȃ is indicated by the arrow. 
[36] 
 
Figure 2.9 shows two peaks for the elution of ¡Ȃǰȱ the first peak appearing asymmetrical, 
suggesting the presence of other ¡Ȃ species. SDS-PAGE analysis was carried out across 
both peaks (Figure 2.10), both peaks protein fractions were then pooled and their A280 
measured before being spin concentrated.  
Some impurities still remain as the band above ¡Ȃ in lane 3 shows (Figure 2.10), as well as 
the band below ¡Ȃ in lanes 1 Ȯ 3. The band below ¡Ȃ in lanes 1 Ȯ 3 is possibly cleaved c 
region of ¡Ȃ; this is because the c region is about 4 kDa in size and ¡Ȃ is about 19 kDa and 
the band below ¡Ȃ is very close to the 15 kDa marker on the gel. However the protein is 




Figure 2.9 Ion Exchange Chrom¢ȱȱ¡Ȃȱ a 5ml Source30Q column 
The absorbance at 280nm is shown by the blue line, while the conductivity is shown by 
































































The Ȃ ion exchange peak however also presented as two peaks, the first being 
asymmetrical (Figure 2.11), meaning there are most likely other Ȃ species present in the 
samples as well, the other species that are possibly present in each of the PDI fragments will 
most likely show up with mass spectrometry.  
SDS-PAGE analysis of fractions taken across the ion exchange peaks is shown in Figure 2.12. 
Ȃ appears to be more pure than both Ȃ¡Ȃ and ¡Ȃ due to the lack of other bands on the 










MW (kDa)    M           1              2            3            4             5            6            7             8             9 
¡Ȃ 
Figure 2.10 SDS-PAGE analysis of ȱ¡ȱȱȱ¡Ȃ 
M is the marker, Lanes 1 Ȯ 9 contain ion exchange samples taken across both peaks. ¡Ȃ 
is indicated by the arrow. 
[38] 
 
After ion exchange chromatography both Ȃ and ¡Ȃ had their protein fractions pooled, 
they were then spin concentrated ready for use in the NMR experiments. Ȃ¡Ȃ went on to 









  M          1          2          3          4         5          6          7          8          9          10         11  
Ȃ 
Figure 2.12 SDS-PAGE analysiȱȱȱ¡ȱȱȱȂ 
M is the marker, Lanes 1 Ȯ 9 contain ion exchange samples taken across both peaks. Ȃ is 
indicated by the arrow. 
ȱŘǯŗŗȱȱ¡ȱ¢ȱȱȂȱȱȱśȱřŖȱ 
The absorbance at 280nm is shown by the blue line, while the conductivity is shown by 























































Elution Volume (ml) 
[39] 
 
2.1.2.3 Gel Filtration 
This purification step was only utilised for the PDI fragment Ȃ¡Ȃ, this was due to it 
previously being reported that a large proportion of the protein dimerises [81], the monomer 
form was required for NMR experiments, so gel filtration chromatography was used to 
separate the monomer from the dimer. 
Figure 2.13 below shows the dimer and the monomer forms coming off the column, the 
second blue peak being the monomer form and the first peak the dimer. As Ȃ¡Ȃ was 
expressed in MM the monomer peak was a lot larger than it would have been if it had been 
expressed in LB media. This was obviously preferential as this means a higher yield of 
useful protein was obtained. Figure 2.14 shows the SDS-PAGE with samples taken across 
both peaks. This demonstrates that both the dimer and monomer samples appear as the 
same molecular weight on a reducing gel. This was the final purification step for Ȃ¡Ȃȱ
























































Elution Volume (ml) 
Figure 2.13 Gel ȱ¢ȱȱȂ¡ȂȱȱȱřŖŖȱ 
The absorbance at 280nm is shown by the blue line and the conductivity shown 




2.1.2.4. Molecular weight and protein yield 
Mass spectrometry was carried out on the purified proteins in both the reduced and non-
reduced states to elucidate their molecular weights. The results are shown below. The mass 
data for Ȃ¡Ȃ is shown as an example (Figure 2.17); both ¡Ȃ and Ȃ were analysed in the 
same manner and are shown in the Appendix Figures 1 and 2 respectively. 
Ȃ¡Ȃ in the non-reduced state presented with a molecular weight of 32466 Da, with four 
other minor peaks at 31693, 32513, 32645 and 32724 Da, one which is 773 Da lighter and 
three which are 47, 179 and 258 Da higher in mass. The reduced protein however showed a 
molecular weight of 32467 Da, with four other peaks as well, one which is 832 Da lighter, 








    M        1           2          3          4          5          6          7          8         9        10      11 
Ȃ¡Ȃ 
Figure 2.14 SDS-PAGE analysis of gel filtration fractions 




Ȃ¡Ȃ non-reduced and reduced had three higher molecular weighted species of about the 
same MW the reduced species being 1 Da smaller than the non-reduced. Both non-reduced 
and reduced presented with degradation products. 
Non- reduced ¡Ȃ has a molecular weight of 19266 Da, with four other peaks, one which is 
lighter at 18472 Da and three which have a higher molecular weight at 19283, 19314 and 
19444 Da, the lighter one being 794 Da less than ¡Ȃ, and the three heavier ones being 17, 48 
and 176 Da higher in mass. Whereas reduced ¡Ȃ has a molecular weight of 19267 Da and 
only two extra peaks at 19314 and 19445 Da, making them 47 and 178 Da higher in mass. 
Both non-reduced and reduced ¡Ȃ showed two higher MW species of about the same size, 
48 and 176 non-reduced, 47 and 178 reduced. The non-reduced ¡Ȃ was the only one to have 
a degradation product, which was at 18472 Da. 
Ȃ in the non-reduced state has a molecular weight of 17376 Da with an extra peak at 17555 
Da, making it 179 Da higher in mass than Ȃ. Reduced Ȃ has the same molecular weight of 
17376 Da and two extra peaks, at 17422 and 17555 Da, which makes them 46 and 179 Da 
higher in mass respectively. 
The non-reduced and reduced Ȃ both presented with one species 179 Da higher in MW. 
All three PDI fragments showed two extra species with MW from 46 to 48 Da higher and 176 
to 179 Da higher than Ȃ. 
The expected MW was taken from was taken from the ExPASy website 
(http://web.expasy.org/protparam/) through entering the amino acid sequence into ProtParam. 
All PDI fragments expected and actual MWȂ from the mass spec. data were almost identical 




Figure 2.15 Expected and actual MW of the PDI fragments in Daltons (Da) 
¡Ȃ proved to have the highest yield as it had a yield of 73.5 mg/L protein purified, in 
comparison only 24.5 mg/L of Ȃ¡Ȃ and 17.7 mg/L of Ȃ was obtained. These quantities 
were calculated from the absorbance at 280 nm of the pooled protein fractions after ion 
exchange chromatography.  
PDI Fragment 
Total Quantity Purified 
(mg) 
Concentration of protein 
produced (mg/L) 
¡Ȃ 44.1 73.5 
Ȃ¡Ȃ 14.7 24.5 
Ȃ 10.6 17.7 
Figure 2.16 Quantity of protein produced from 600ml cell culture as well as its 
concentration  
 
PDI Fragment Expected MW (Da) 
Mass Spec. Data 
(Da) Non-Reduced 
Mass Spec. Data 
(Da) Reduced 
¡Ȃ 19267.3 19266.0 19267.0 
Ȃ¡Ȃ 32467.5 32466.0 32467.0 
Ȃ 17377.1 17376.0 17376.0 
[43] 
 
   
A 
B    
Figure 2.17 Mass spectrometry analysis of bȂ¡ȂȱȱȱȱǻǼȱȱnon-reduced 
(B) forms. 
The molecular weight of Ȃ¡Ȃ in daltons, in its reduced form is 32467 Da and in its non-
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2.2. PDI Ligand 
2.2.1. Expression 
Again, SDS-PAGE analysis was used at each stage of the purification process to aid in 
characterising the protein and to act as another way of making sure the protein made it 
through the purification step in high enough quantities.  
Figure 2.18 below shows the expression of a small prep. and 3 large growth cultures.  Pre 
and post IPTG induction of GB1-‚E-somatostatin is shown with an expected molecular 
weight of 10 kDa. The control GB1 was analysed in the same manner for its pre and post 



























































































Figure 2.18 SDS-PAGE analysis of pre and post IPTG induction of GB1-AE-
somatostatin 
Precision plus marker is shown on the left hand sides of the pre and post IPTG sample 




The pre and post IPTG SDS-	Ȃs for both GB1 and GB1-‚E-somatostatin both presented 
with bands just above the 10 kDa marker band despite their respective molecular weights 
being 8 kDa and 10 kDa. 
2.1.2. Purification 
Nickel affinity chromatography is the only purification step utilised for the PDI ligands, the 
double His-tag on the N-terminal of the protein allows the constructs to bind to the nickel in 
the column whereas the protein impurities are washed out. 
2.1.2.1. Nickel Affinity Chromatography 
Again this purification process proved to be extremely effective in removing the vast 
majority of impurities after cell lysis. The buffer running through the column was collected 
in 2 ml fractions and its A280 was measured and plotted on a graph (Figure 2.19), allowing 
the tracking of the protein as it comes off the column.  
The total lysis, supernatant, pellet, flow through, wash peak and elution peak fractions were 
all prepared in the same manner as the PDI fragments post nickel column SDS-PAGE 
samples. The pellet sample of both GB1 and GB1-‚E-som did not contain any of the ligand, 
showing total lysis of the cell. The flow through and wash peak samples did not show any 
bands for GB1 or GB1-‚E-som, showing that all the ligand had bound to the column and was 
not washed out by the wash buffer (50 mM Imidazole).  
As this is the only purification step for the PDI ligands, both GB1 and GB1-‚E-somȂȱ -
	Ȃȱȱ ȱin Figure 2.20. Again, just like with the pre and post IPTG samples, the 
GB1 and GB1-‚E-som fractions run to just above 10 kDa despite their respective molecular 






























Fraction Number (2ml fractions) 
Figure 2.19 Nickel affinity chromatography of GB1-AE-somatostatin 
The absorbance at 280nm of the samples is shown, B is when the binding buffer is added, 
W is when the wash buffer was added and E is when the elution buffer was added. The 









































































































































































Figure 2.20 SDS-PAGE analysis of GB1 and GB1-AE-som by nickel affinity 
chromatography  
Precision plus marker is shown on the left hand side, with total lysis, supernatant, pellet, 
flow through, and the wash fraction (50 mM imidazole), the fractions after are taken 
across the elution peak (20 mM EDTA). GB1-‚E-somatostatin is indicated by the arrow on 




After nickel column chromatography the protein fraction samples were pooled and dialysed 
ready for spin concentration. Once spin concentrated the protein is ready for the NMR 
experiments. 
2.1.2.2. Molecular weight and protein yield 
Just like with the PDI fragments, mass spectrometry was utilised to elucidate the molecular 
weight of the proteins expressed, the results of which are shown below.  
 GB1 presented with a molecular weight of 7957 Da (mass spec. data shown in Figure 2.23) 
despite it presenting with a molecular weight of about 10 kDa on the SDS-PAGE gels that 
were run. Three other molecular weights of GB1 were also shown to be present in the 
purified sample, 7974, 8010 and 8064 Da, this makes the other peaks 17, 53 and 107 Da larger 
respectively GB1-‚E-somatostatin presented with a molecular weight of 10147 Da with only 
one other peak at 10200 Da, which meanȱȂȱśřȱȱȱȱǯ The + 53 Da species is 
present in both GB1 and GB1-‚E-som. 
Figure 2.21 Expected and actual molecular weight of both GB1 and GB1-AE-som 
Total quantity purified was calculated in exactly the same way as the PDI fragments in 
Figure 2.16, the results of which are shown in Figure 2.22. GB1-‚E-som appears to have 
purified a lot more effectively than just GB1 on its own. 
Figure 2.22 Quantity of protein produced from 600ml cell culture as well as its 
concentration 
PDI Ligand Expected MW (Da) Mass Spec. Data MW (Da) 
GB1 7957.6 7957.0 




Concentration of protein in 
600 ml culture (mg/L) 
GB1 8.17 13.62 











Figure 2.23 Mass spectrometry data for GB1 (A) and GB1-AE-somatostatin (B) 
GB1 shown to be 7957 Da and GB1-‚E-som to be 10147 Da. GB1 with three other peaks 


















































Both the PDI fragments and PDI ligands were successfully expressed in E. coli BL21 (DE3) 
pLysS and purified using the various purification techniques demonstrated above showing 
various expression yields.  
The first purification step, nickel column chromatography, proved to be an extremely 
effective way to purify the PDI fragments and ligands, due to the massive reduction in both 
low and high MW impurities. Although the purification protocol might still have room for 
optimisation due to there being no band at all of the desired protein in the wash peak 
sample as shown in Figures 2.6 and 2.20. This optimisation could be achieved through 
slightly increasing the concentration of imidazole in the wash buffer; this would be most 
useful for the PDI ligand purification as its purification is still to be optimised due to the 
presence of high MW bands being present in Figure 2.20. Ion exchange chromatography was 
not used for the ligands partly because the nickel column step was so successful, but mainly 
because of time limitations and that the protein was sufficiently pure for the experiments 
planned. The fact that more protein would be lost with another purification step was also a 
factor. Also in Figures 2.6 there was an indication that lysis of the cells was not complete due 
to the presence of the PDI fragments bands showing in the pellet, this is either due to human 
error or the protocol needs tweaking, most likely the former as this is a well-established 
protocol for lysing cells. Very faint bands were showing for the PDI ligand pellet indicating 
almost complete lysis, this showed that lysis by sonication was an effective technique for the 
PDI ligand pellet, shown in Figure 2.20. 
It should be mentioned that both PDI ligands, GB1 and GB1-‚E-som presented with slightly 
ȱ Ȃȱ ȱ ŗŖȱ ȱ  ȱ ¢ȱ ȱ -	Ȃǰȱ ȱ  ȱ ȱ ȱ
[50] 
 
spectrometry showing GB1 to have a MW of 7957 Da, it is unclear as to why this happened, 
although this was shown to be the case for each SDS-PAGE analysis performed on GB1. 
Ion exchange chromatography was also very useful for further purifying the PDI fragments, 
as it removed the vast majority of the impurities left after the nickel column step. Due to the 
asymmetrical peaks forming from ion exchange chromatography for ¡Ȃ and Ȃȱ (Figures 
2.9 and 2.11 respectively), it was expected for there to be multiple species of these constructs, 
this was proven to be correct as the mass spectrometry data showed. Ȃ¡Ȃ displayed a 
symmetrical peak, however other Ȃ¡Ȃ species were present as shown in Figure 2.17, 
indicating that a symmetrical peak Ȃȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ ȱ
present. 
Gel filtration chromatography was the final purification process for the PDI fragment Ȃ¡Ȃ 
ȱȂȱ ȱto contain a large amount of dimer. For this reason when unlabelled Ȃ¡Ȃ was 
needed, it was also grown in MM. This was because in LB media, E. coli have a much faster 
growth rate and thus a much faster protein expression rate, this meant that in LB media 
Ȃ¡Ȃ would be expressed very quickly, leading to close proximity of folding proteins, 
resulting in much higher levels of dimerization (unpublished observation from previous 
work in the lab). MM on the other hand would most likely express Ȃ¡Ȃ at a slower rate 
due to the lack of free amino acids and trace elements etc, allowing the protein to fold 
properly.  
¡Ȃ and Ȃ presented with two peaks, the most probable reason for the two distinct peaks is 
¡Ȃ and Ȃ in the reduced and non-reduced forms coming off the column at different times 
due to slight changes in their isoelectric points.  
[51] 
 
The majority of the extra peaks shown in the mass spectrometry data were higher in MW 
than the desired protein; these are either post-translational modifications or something 
within the purification process itself which is binding to these constructs. All the PDI 
fragments showed degradation products, however the PDI ligands did not. 
The PDI fragment mass spec. data showed species that were 178 and 258 Da higher in MW 
than the desired proteins, these can be attributed to the post translational modification 
which involves the alpha-N-6-phosphogluconoylation of the proteins His-tag, this results in 
the species 178 Da higher in mass and only sometimes the species 258 Da higher in mass 
[82].This explains why the + 258 Da species was present in Ȃ¡Ȃ but not in the other PDI 
fragments whereas derivatives of the + 178 Da species was present in all three PDI 
fragments. However it is unclear why this modification did not occur for the PDI ligands. It 
should be noted that this modification did not alter the purification during ion exchange 
chromatography due to the modifications being in such low quantities.  
The presence of the + 46 to + 48 Da species was present in all three PDI fragments and could 
possibly be attributed to oxidative modification to kyneurine (+ 4 Da), singly oxidised 
tryptophan (+ 16 Da) and hydroxy-N-formyl kyneurine (+ 48 Da), the + 17 Da species of ¡Ȃ 
and GB1 might also be accounted for due to this [83]. 
+ 53 Da  species was present in both GB1 and GB1-‚E-som, although another two were 
present in GB1 at + 17 and + 107 Da, the extra + 107 Da peak possibly 2 x the + 53 Da post 
translational modification. Although at the moment it is unclear as to what the + 53 Da 
modification could be. 
[52] 
 
¡Ȃ was shown to have the best expression yield of the PDI fragments at 73.54 mg/L, with 
Ȃ¡Ȃ a distant 2nd with just over a third of ¡Ȃ protein yield at 24.56 mg/L and Ȃ a close 3rd 
with 17.72 mg/L. Ȃ produced a surprisingly low yield in comparison to ¡Ȃ, this could 
indicate that the x linker of ¡Ȃ helps to stabilise it, preventing it from being degraded so 
quickly, although it could possibly be attributed to human error during the expression and 
purification process.  
The protein yield for GB1 was surprisingly low at 13.62 mg/L whereas GB1-‚E-som yield was 
32.60 mg/L, this is in comparison to the higher expression yields (20 mg/L) described in the 
literature [84], whereas the protein yield for GB1-‚E-som agrees with the literature of the 
other purified fusion proteins GST and MBP (15 to 50 mg/L) [85]. This reduction in GB1 














1.0 Redox potential of the Ȃ domain 
 
1.1 Introduction 
A vast number of reactions catalysed by enzymes are reduction-oxidation reactions. This 
reaction involves the reduction of one compound and the oxidisation of another. Enzymes 
can only catalyse these reactions however in the right environment, described as its 
reduction potential or redox potential. Redox potential varies from compound to compound; 
the more positive itȂs potential, the more likely it is to accept electrons and become reduced, 
therefore showing oxidising characteristics and the more negative the redox potential the 
more likely it is to be oxidised and exhibit reducing properties.  
Protein reduction potentials have typically been elucidated in the past via the use of 
tryptophan fluorescence or through the use of radiolabelling or HPLC. However these 
methods can only be utilised when there is just one catalytically active site present, as these 
[54] 
 
methods work by separating and quantifying the different amounts of reduced and oxidised 
species of the protein present.  
ȱȱȱȱ¡ȱȱȱȂȱȂ domain is investigated through the addition 
of domains surrounding Ȃ, NMR spectrometry is utilised with HSQC experiments to gather 
data on this, see Taylor, S., et al., 2013 [86]. This adds to our understanding of the overall 
redox potential of PDI, allowing us to develop a more complete picture of its role in vivo. 
1.2 Redox-dependent conformational change of hPDI 
PDI is a redox regulated chaperone protein which undergoes large redox dependent 
changes to its conformation [30], Ȃ¡Ȃ being the minimal number of domains required for 
PDI to undergo redox regulated conformational change, with the Ȃ domain being the key 
domain to induce conformational change once oxidised. The PDI domain region Ȃ¡Ȃ 
showed that the Ȃ domain was situated closely to both the Ȃ domain and x linker, to form 
one tightly bound structural module. Once the Ȃ domain is oxidised the compact structure 
is lost, exposing the substrate binding site of the Ȃ domain, allowing hPDI to undergo its 
chaperone function [30], [31]. 
In the reduced state all 4 main domains of PDI are on the same plane, whereas in the 
oxidised state, the Ȃ domain twists around the x linker at about a 45° angle above the plane, 
this explains why in the reduced state, the a and Ȃ domains are 27.6 Angstroms (Å) apart 
ȱ ȱ ȱ¡ȱ ȱ ¢Ȃȱ ŚŖǯřȱ#ȱ (Figure 3.1). This means that in the reduced 
state hPDI reveals a smaller hydrophobic surface ȱ ȱȂȱ the more open oxidised 




ȱȱȱȱȱȱȱȂȱȱ¢ǯȱȱȂ domain triggers 
this conformational change as the amino acid residue Trp396, adjacent to the active site, 
interacts with the bȂ domain when it is in the reduced state, however in the oxidised state, 
the residue is exposed [31]. ȱȱȱȱȱȱȱȂȱȱȱȱȱ
appears to play a role in sensing the change in redox state. The ‚?Ř-‚?ř loop of the aȂ domain 
is also involved in conformational change as it interacts with Ȃ in the reduced state and is 
exposed when PDI is in the oxidised state [31].  
Another region which may play an important role in the sensing of changes in the redox 
conditions is the highly conserved, among thioredoxin-like proteins, Pro441. This residue is 
also located adjacent to the active site, just like Trp396, and has been shown to be an 
important part of substrate binding and release; this is based on studies conducted on DsbA, 
thioredoxin and yPDI [29], [87], [88]. PDI was first shown to be a redox regulated chaperone 
Figure 3.1 Crystal structure of (A) reduced and (B) oxidised PDI 
a domain shown in red, b domain in blue, Ȃ domain in light blue, x linker in purple and 
Ȃ domain in pink. Both a and Ȃ domains active sites highlighted in green. 
Representing the distance between the active sites in Angstroms (Å) in the reduced (A) 
and oxidised (B) states.  




in 2001 due to it binding to and unfolding the cholera toxin A1 subunit in the reduced form 
[89].  
1.3 Redox potential of hPDI overview 
PDI catalyses the formation of disulphides as well as retaining the ability to re-arrange non-
native disulphides in an isomerisation reaction. Fȱ ȱ ȱ ȱ Ȃȱ ȱ ȱ ¡ȱ
potentials must be placed in a position so that they can both donate electrons (to Ero1) and 
take them (from substrates) [90]. 
In 1993 PDI was demonstrated to have a redox potential of -190 +/- 10 mV, in the same 
paper, its dithiol active sites were shown to have a redox potential of roughly -175 mV +/- 15 
mV [91]. In 2010, a paper was published showing a more accurate redox potential 
measurement for domains a and Ȃ, -162.7 +/- 2.9 and -169.4 +/- 2.3 mV respectively [90]. This 
indicated that, during disulphide exchange reactions, any difference in the amount of 
reactivity would most likely not be due to the difference in redox potential. In the study the 
CGHC active site motif was changed to CGPC, this changed the a and Ȃ domains redox 
potential to -228.9 +/- 0.6 and -225.9 +/- 2.6 mV respectively, making them more reducing and 
ȱ ȱȱȱȱ¡ȱȱȱȱ¢ȱŗ‚?ǯȱȱ ȱȱȱȱ
use of site directed mutagenesis and mass spectrometry; this helped to show how the 
reduction potential of hPDI active sites limited the re-¡ȱ¢ȱȱŗ‚?ǯȱȱ¢ȱ
ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ ȱ ȱ ȱ ȱ





1.4 15N/1H HSQC Experiments 
HSQC experiments were used in this study as they are quick to run and produce high 
quality data. 
Ȃȱ allow you to see a single peak for each amino acid residue, except 
proline as it does not contain an amide group. These peaks shift in position due to 
environmental changes such as pH, temperature or the presence of a reductant or oxidant. 
An improved method to elucidate redox potentials via the use of 15N/1
ȱ
Ȃȱ ȱsed in 
this study, first demonstrated by Taylor S.L., et al, 2013 [86], this method was used due to it 
being quick and convenient, as well as it suiting the size of the proteins, as the MW limit for 
this method is in excess of 60 kDa whereas the proteins used only go up to 32 kDa. It uses 
multiple resonances to elucidate the redox potential, meaning a degree of data redundancy 
can be implemented as weak, overlapping or low signal to noise ratios data can be discarded 
from the analysis leading to improved accuracy of the redox potential. I refer the reader to 
the paper Taylor S.L. et al, 2013 [86] for further clarification if required. 
It should be noted that these redox potential calculations are carried out on an in vitro 
system and therefore are not open to the different altering factors encountered in an in vivo 
measurement, and so may differ slightly. 
1.5 Redox Couples 
1.5.1 GSH/GSSG 
The main redox couple used throughout this thesis was reduced and oxidised glutathione 
(GSH and GSSG respectively). Glutathione  (structure shown in Figure 3.2) is the model 
redox couple for these experiments as it is found within the ER in the optimum ratio for 
disulphide bond formation [92]. The ratio of GSH to GSSG was reported to be between 1:1 
[58] 
 
and 1:3 in the secretion pathway and microsomal vesicles, this is based on an in vitro study 
that showed the oxidative folding of proteins in redox buffers with a similar ratio of 
GSH:GSSG [93], [94]. 
GSH is a tripeptide (L-‚?-glutamyl-L-cysteinyl-glycine) and is synthesised from the precursor 
amino acids glutamate, cysteine and glycine in the cytosol in concentrations up to 10 mM. 
Glutathione remains in the reduced form (GSH) due to the cytosolic glutathione reductase 
catalysed reaction with NADPH [95]. All this makes GSH/GSSG the natural model for redox 
couple reaction experiments. 
Rost and Rapport [96] were the first to give the redox potential of GSH/GSSG as -240 mV 
[96], this is the redox potential used for the calculations in this chapter. 
 
In recent years the hypothesis that GSSG was the main route through which PDI was 
oxidised was called in to question by the discovery of Ero1 [97], [98]. It was shown that yeast 
cells carrying a mutant Ero1 had their normal level of oxidised PDI severely reduced when 
Ero1 was not functioning. It was also shown that the oxidation of Ero1 substrates is largely 
independent of the redox buffer glutathione [99]. 
2 
Figure 3.2 Showing reduced glutathione (left) and oxidised glutathione (right) 
Skeletal structure of GSH and GSSG adapted from Sigma-Aldrich 
 
GSH GSSG 




Dithiothreitol (DTT, HSCH2(CH(OH))2CH2SH) was also used at times due to its extreme 
reducing abilities  with a redox potential of -332 mV at pH 7 [100]. However DTT did not 
work very well as a redox couple due to its oxidising form not being oxidising enough, this 






2H+ + 2e- 
Figure 3.3 Showing reduced DTT (left) and oxidised DTT (right) 




The redox potential was determined using various ratios of GSH and GSSG, the total 
concentration equalling 5 mM. This was to oxidise and reduce the purified protein to 
varying degrees; equilibrium for these reactions was reached within 5 min of setting up each 
sample. Peaks in the HSQC spectra were identified which shifted with the oxidation status. 
The NMR data gathered from these peaks was presented as peak height or peak volume, 
either parameter could be used to calculate the redox potential; however the peak volume 
tended to give better fits with the Hill equation and so was used. Analysis v2.2 [73] was 
used to determine the peak heights and volumes for all the oxidised and reduced peaks.  
The data collected was then used to calculate the fraction reduced of each of the peaks and 
fitted using Kaleidograph v4.1 (Synergy Software) to the Hill equation.  
The Keq value was calculated from Figure 3.4 A at the point at which the Fraction reduced 
(Fred) equals 0.5. This is the point at which the ratio of GSH:GSSG changes the least and 
therefore should provide the most accurate redox potential. Keq is then put into the Nernst 
equation (Figure 3.4 B) to calculate the redox potential, where the standard reduction 
A. Fraction Reduced 
Fred = ([GSH]2 / [GSSG] / (Keq +[GSH]2 / [GSSG]) 
B. Nernst Equation 
Eȝ0 = Eȝ0(GSH) ƺ (RT / nF)ln(Keq) 
Figure 3.4 Fraction reduced and Nernst equations used to calculate redox potential 
Adapted from Taylor S.L., et al, 2013 [86]. 
[61] 
 
potential of GSH (Eȝ0(GSH)) = -0.24 V, R is the molar gas constant, T = 298 K, n = 2 , F is the 
Faraday constant. Keq must be used in molar concentration. Errors were calculated using the 
Levenberg-Marquardt R value for the fit of the Hill equation. 
¡Ȃ and Ȃ¡Ȃ were assigned using assignments determined previously (unpublished data) 
by Dr Denisa Doko [81]. 
Řǯŗȱ¡Ȃ 
¡Ȃ proved to be the easiest PDI construct to use throughout this thesis. It expressed highly 
as well as being easy to analyse through NMR spectrometry due to its stable conformation. 
As the Ȃ domain has previously been reported to be difficult to work with as it has a low 
expression yield (approximately 1 mg/L) and exhibits very poor NMR spectra. The addition 
of the x linker and the c region helped to stabilise the construct. 
HSQC 
A fully assigned reduced spectrum (using 5 mM GSH), shown below in Figure 3.5 was used 
to calculate the fraction reduced of the other spectra, as the fully reduced was used as the 



















HSQC redox calculations 
The peaks for ¡Ȃ identified which move in the different oxidation states were G462, T411, 
T445, Q350 and A387. The fully reduced and fully oxidiȱ
Ȃȱȱ ȱin Figure 3.6 






Figure 3.6 Two NMR 15N HSQC spectraȂȱȱ¢ȱȱȱ¢ȱ¡ȱ¡Ȃȱ 
Fully oxidised (with 5 mM GSSG) spectra are shown in red and fully reduced (with 5 
mM GSH) spectra shown in blue. The amino acid residues G462, T411, T445, Q350 and 









Fraction Reduced   
The plot for each amino acid residues fraction reduced shown in Figure 3.7 for ¡Ȃ, this is 
used as an example for the other redox calculations. Figure 3.7 was used to calculate the 
average fraction reduced, with the average calculated from the sum of the 5 residues at each 




Figure 3.7 ¡Ȃȱȱǰȱȱȱv4.1 (Synergy Software) to fit the 
Hill equation 
All data sets for amino acid residues G462, T411, T445, Q350 and A387. Ratio of 




Average Fraction Reduced 
¡Ȃ exhibited very consistent NMR data, as the loss of peak intensity for the reduced peaks 
due to oxidation was easily trackable. The redox potential is calculated from the point at 
which the curve crosses the y axis at 0.5 (Figure 3.8). This y value was used as Fred in the 
Fraction reduced equation (Figure 3.4 A) to calculate the value of Keq. This allows you to 
calculate the redox potential using the Nernst equation. The redox potential was calculated 
the same way for each PDI construct. From this graph the redox potential was calculated 
and found to be -196.23 mV +/- 0.42. 
Figure 3.8 ¡Ȃȱverage fraction reduced, using Kaleidograph v4.1 (Synergy Software) 
to fit the Hill equation 
Average of data sets for Figure 3.7, with the ratio of GSH:GSSG on the x axis and average 





This construct was a lot more difficult to work with, the addition of the Ȃ domain seemed to 
increase line broadening for all the peak resonances massively decreasing the quality of the 
spectra. It also rapidly aggregated in solution when it was fully oxidised with 5 mM GSSG, 
and did not become fully reduced in the presence of 5 mM GSH as shown in Figure 3.9, so 
1.5 mM of DTT was used instead to fully reduce it, due to its reduction potential being -332 
ǰȱȱȱȱ	
Ȃȱ-240 mV. This improved the resolution of the spectrum (shown in 
Figure 3.10) however the spectrum was still broad compared to ¡Ȃ. The number of residues 
identified to shift on oxidation and used for the redox calculation was 11 in total.  
 
Figure 3.9 NMR 15N 
ȱȱȱ¡Ȃ 




Figure 3.10 showing the partially assigned spectrum of Ȃ¡Ȃ. The spectrum is only 
partially assigned as it was not possible to assign past this point with any accuracy 






Figure 3.10 NMR 15N HSQC spectra of bxaȂ 
NMR 15ȱ
ȱȱȱȂ¡Ȃȱȱȱ¢ȱȱȱ ȱŗǯśȱȱǯȱ¢ȱ





The residues identified were E293, I240, K292, W390, N413, F265, C295, A262, A387, L285, 
K398 and E304 shown below in Figure 3.11. The fully reduced spectra with 1.5 mM DTT 







Figure 3.11 Two NMR 15N 
ȱȂȱȱ¢ȱȱȱ¢ȱ¡ȱȂ¡Ȃȱ 
Fully oxidised (with 5 mM GSSG) spectra are shown in red and fully reduced (with 1.5 
mM DTT) spectra shown in blue. The amino acid residues W390, K292, I240, E293, N413, 


















From 0.5 of the y axis from Figure 3.12 it was possible to calculate the redox potential to be -
213.71 mV +/- 0.16. This means that the addition of the Ȃ domain on to ¡Ȃ decreases the 
redox potential from -196.23 to -213.71 mVǰȱ ȱ Ȃȱ ȱ , this is a total 
decrease of 17.48 mV. 
 
Figure 3.12 ¡Ȃȱ ȱ ȱ ǰȱ ȱ Kaleidograph v4.1 (Synergy 
Software) to fit the Hill equation 
The ratio of GSH:GSSG on the x axis and average fraction reduced on the y axis. Ȃ¡Ȃ 





It has been previously reported that the Ȃ domain is notoriously difficult to characterise 
through NMR, the addition of the c-region stabilised the construct and allowed for a higher 
yield in purification as well as improved resolution in the NMR spectra with the 
unstructured c region appearing as peaks between 8 and 8.5 ppm, typical for an 
unstructured region. However Ȃ proved to be very problematic when attempting to 
calculate its redox potential. The PDI fragment was not reduced enough by 5 mM GSH (as 
shown in Figure 3.13), ȱ ȱ 	
Ȧ		ȱ ¡ȱ ȱ  Ȃȱ  ǯȱ ȱ ȱ
oxidised DTT was then used, which also proved to have its own difficulties, as it was able to 
improve the quality of the spectra collected when it was fully reduced (as shown below in 
Figure 3.14) but oxDTT was unable to oxidise it enough to track any change. Also the data 





Figure 3.14 NMR 15N 
ȱȱȱȂ 
NMR 15N HSQC spectra of Ȃ in the fully reduced state with 1.5 mM DTT. 
Figure 3.13 NMR 15N 
ȱȱȱȂ 




 ¡Ȃ Ȃ¡Ȃ 
Number of resonances 5 11 
Keq (M) 0.033 0.129 
Ȃ0 (mV) -196.23 +/- 0.42 -213.71 +/- 0.16 
Figure 3.15 Keq and the reduction potentials (Eȝ0) determined for the PDI fragments ¡Ȃ 






Protein disulphide isomerase is a multidomain protein functioning as a redox regulated 
chaperone protein. It undergoes large redox dependent changes to its conformation to allow 
it to perform both oxidative folding and reductive unfolding of its protein substrates. As PDI 
is able to undergo these conformational changes, it is able to bind to an extremely broad 
range of substrates [61], [101]. The conformational changes hPDI undergoes are essential to 
the regulation of its chaperone activity. As PDI needs to act as both an oxidase as well as an 
isomerase protein; the active sites of PDI need to balance in between the redox potentials 
that are required, so that they can be reduced or oxidised when required [90]. 
The redox potentials of ¡Ȃ and Ȃ¡Ȃ were found to be -196.23 +/- 0.42 mV and -213.71 +/- 
0.16 mV respectively, showing that the redox potential shifts to be more negative when the 
Ȃ domain is added to the ¡Ȃȱfragment. This means that with the addition of the Ȃ domain, 
the fragment becomes a lot more reducing and therefore allowing the fragment to be re-
oxidised a lot more easily. This also indicates some form of communication between the Ȃ 
and Ȃ domains. 
¡Ȃȱ 
¡Ȃ proved to have a stable conformation throughout the NMR experiments, and was 
predicted to have a redox potential more positive than -ŘŚŖȱȱǻ	
Ȃȱ¡ȱǼȱȱ
to 5 mM of GSH being able to fully reduce the protein. This was proven to be the case as ¡Ȃ 
was shown to have a redox potential of -196.23 mV. As it has been previously reported that 
the Ȃ domains redox potential is -169.4 +/- 2.3 mV [90], the addition of the x linker and the c 
region not only stabilise the Ȃ domain structurally but also reduce its redox potential by 
26.83 mV to -196.23 +/- 0.61 mV. Keq for a and Ȃȱ domains are 2.6x10-3 and 4.4x10-3 M 
[74] 
 
respectively in the full PDI protein [90], whereas on their own they are 7x10-4 and 1.9x10-3 M 
respectively [102], this is in contrast to the equilibrium constant (Keq) of 0.033 M calculated 
for ¡Ȃ. 
Ȃ¡Ȃ 
The redox potential of Ȃ¡Ȃ was thought to more negative than ¡Ȃ, this is due to one of 
the first results gathered for Ȃ¡Ȃ, the 5 mM GSH sample (Figure 3.9). As GSH was unable 
to fully reduce Ȃ¡Ȃȱwe came to the conclusion that Ȃ¡Ȃ must have a lower reduction 
potential than ¡Ȃ. This was proven as DTT was able to fully reduce it (Figure 3.10) even 
though it presented with broad peaks suggesting conformational instability. Ȃ¡Ȃ 
conformational instability could be partly due to the  flexibility of the x linker, the N-
terminal region of the x linker has been reported to stabilise the Ȃ domain [103], on the 
other hand the C-terminal region of the x linker only loosely binds to the Ȃ domain and does 
not contribute to the stability of Ȃ structure. This could account for why Ȃ¡Ȃ appears to 
undergo a lot of conformational change in different redox states [101].  
Decrease in redox potential from ¡Ȃ to Ȃ¡Ȃ was a difference of 17.48 mV, meaning the 
difference in reduction potential can be put down to the addition of the Ȃ domain. This 
means Ȃ¡Ȃ is a stronger reductant (redox potential more negative), meaning the fragments 
isomerase activity would be increased but its oxidase activity would be decreased. 
The aggregation that occurred in many of the fully oxidised Ȃ¡Ȃ NMR samples could be 
due to the change in conformation of the fragment making the hydrophobic binding site of 
Ȃȱmore exposed and therefore resulting in aggregation due to hydrophobic interactions. 
This was the only PDI fragment used in this work where aggregation was an issue. 
[75] 
 
Capping of the Ȃ domain using an I272A mutant has been used previously to improve 
conformational stability, however this would affect the redox potential so the wild type was 
used instead [61].  
Ȃ 
The redox potential for Ȃ appeared to be unobtainable, the addition of 5 ȱ	
ȱȂȱ
seem to reduce the protein to even the same level as Ȃ¡Ȃ, indicating that the reduction 
potential for Ȃ will be even more reducing than both ¡Ȃ and Ȃ¡Ȃ. This indicates that the 
addition of the x linker has a big effect on Ȃ, even more so than the addition of Ȃ¡.  
 Ȃ¡Ȃ had a redox potential of -213.71 mV, this was reaching the limits of what the 
GSH/GSSG redox couple could achieve, as it can only go down to -240 mV, thȂȱ ¢ȱȱ
was used (-332 mV). As DTT was so reducing it had to be used in such small quantities that 
the bands for error were very high. In hindsight, it would have been better to try and 
ȱ ȱ ¡ȱ ȱ ȱ ȱ ȱ ȱ ȱ  ȱȱ ȱ	
ǰȱ ȱ ȱ ‚?-
mercaptoethanol (-260 mV) or lipoic acid (-288 mV). 
It was initially suspected that Ȃ had unfolded due to Figure 3.13 showing no peaks either 
side of the unstructured c region in the presence of 5 mM GSH, but through the addition of 
1.5 mM DTT this was shown not to be the case (Figure 3.14). This suggests that Ȃ exhibits 








1.0 Ligand Binding 
1.1 Introduction 
Ȃȱȱȱǰȱȱȱȱ¢ȱ aspect for the function of 
the protein and having a long history of research based on this topic, is still not fully 
understood. This chapter aims to help further clarify the ligand binding behaviour of hPDI 
ȱȱȱȱ‚E-somatostatin. 
The most recent research in this area by Yagi-Utsumi M., et al. in 2015 [104] has been able to 
elucidate the three dimensional structure of PDI in thermophilic fungus (Humicola insolens) 
in relation to its ligand binding mode. Through the use of NMR and X-ray crystallography it 
 ȱ  ȱ ȱ ȱȱ ȱ‚?-¢ȱ ǻ‚?Ǽȱȱ ȱȱȱ ȱ¢obic 
‚?ȱȱřŝ-Val40 (Val-Leu-Tyr-Val) only in the oxidised form. It was also reported 
by the same paper that through comparison of the crystal structure of the fragment Ȃ¡Ȃ 
with previously reported crystal structures, the Ȃ domain partially covers the Ȃ binding 
domain (Figure 4.1), causing steric hindrance fore substrate binding when Ȃ¡Ȃ is in the 
ȱǯȱȱ‚?ȱ site largely overlaps with that of the same Ȃ surface known 
ȱȱȱȱȱ ȱ‚E-somatostatin [104].  
[77] 
 
The binding site characterised in the PDI of Humicola insolens is located towards the N-
terminal of the Ȃ domain [104], whereas in hPDI, the Ȃ domains binding site is bigger and 
the residues involved are located across a Ȃ ‚?ȱȱȱ ȱȱȱȱ-terminal half of the 
protein [60], [105]. 
Other research in this area has further characterised the binding behaviour of hPDI via the 
use of the model ligand ‚E-somatostatin, this research was also conducted from both the 
view of the ligand and the protein [106]. ‚E-som does not contain valine or leucine residues, 
 ȱ  ȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ ‚?ȱ ȱ ȱȱ Humicola insolens PDI, 
implying that the fungal PDI has a distinctive substrate recognition mechanism in 
comparison to hPDI [104], [106]. 
Richards, K.L., et al., 2015 [106] demonstrated the importance of ‚E-sȂ three 
phenylalanine residues (mainly Phe11) in the interaction between ‚E-som and hPDI. All three 
phenylalanine residues in ‚E-som are involved in its recognition by bȂ¡ of hPDI, removal of 
Figure 4.1 Model of redox dependent ligand binding 
Substrate shown in blue with hydrophobic domains shown in orange. Showing open 
conformation of PDI in the oxidised form with the hydrophobic segment of the substrate 
binding to the hydrophobic domain of Ȃ, whereas with the reduction of Ȃ, the Ȃ and Ȃ 
domains interact forming a closed conformation, leading to release of the substrate with 
disulphide formation. 
Adapted from Yagi-Utsumi M., et al., 2015 [104] 
[78] 
 
phenylalanine causes ‚E-som not to be recognised by Ȃ¡ whereas removal of one or two of 
them leads to a much lower binding affinity.  
The ligand binding site of hPDI has been extensively mapped through the use of NMR [60], 
[61], [107], it has also been shown that the Ȃ binding domain is capable of binding to 
peptides in the size range of 10 to 15 residues long independently of disulphide bonds but 
through hydrophobic interactions [103], and that the binding of larger peptides and non-
native proteins however requires additional binding contributions from both the a and Ȃ 
domains [108]. 
Previous studies have shown that GB1 fusion proteins can be directly used in NMR studies 
involving lipids such as micelles, bicelles or liposomes, as GB1 on its own does not 
significantly interact with the lipids, so any chemical shift seen with the GB1 fusion protein 
can be attributed to the fusion [109]. In this chapter ligand binding behaviour of hPDI is 
ȱȱȱȱ ȱȱȱȱ‚E-somatostatin. GB1 is also investigated to 
determine whether it interacts with Ȃ¡Ȃ to determine whether GB1 fused to ‚E-som can be 
used in future ligand binding experiments or whether the ligand has to be cleaved off GB1 
first. This means that the cleaving of GB1 from the ligand is potentially unnecessary and can 
be avoided. Additionally the cleavage is not always complete or could even lead to the 
digest of the target ligand itself. Also another purification step would be required to remove 
the cleaved GB1 from the sample leading to a smaller overall yield as some ligand will be 





To achieve this, 15N labelled GB1-‚E-som as well as unlabelled Ȃ¡Ȃ, were expressed and 
purified. Bonding of Ȃ¡Ȃ to GB1-‚E-som was analysed on both reducing and oxidising 
conditions. Peak shifts in 15N/1H HSQC spectra were identified and measured. This method 
has been extensively documented to determine chemical shift perturbations via NMR [110], 
[111]. A control of GB1 without fusion was also used to see if there was any interaction 
between GB1 alone and Ȃ¡Ȃ. 
1.2 GB1-AE-somatostatin 
Expressing ‚E-somatostatin (structure shown in Figure 4.2) on its own in E. coli would lead 
to high levels of degradation. Therefore the fusion protein GB1 was employed to prevent 
this. This fusion protein is the B1 domain of the Streptococcus protein (GB1). It folds into a 
3D structure and is fused to ‚E-som to increase expression yield and stability [112]. 
The GB1-‚E-som fusion has a His-tag at its N-terminus to enable purification via nickel 
affinity chromatography, and although it has been reported to lower the expression by some 
[113], it has also been reported to increase protein yield and purity [84], [113],  
as well as enhancing the peptide stability six fold [84]. 
  
Figure 4.2 Stick model of AE-somatostatin showing all amino acids 




GB1 and GB1-‚E-som were compared directly by the chemical shifts of GB1 being measured. 
Both GB1 and GB1-‚E-som have their chemical shifts measured in the presence of Ȃ¡Ȃ in 
either the fully reduced (with 1.5 mM DTT) or fully oxidised (with 5 mM GSSG) states. 
Ȃ¡Ȃ without reductant or oxidant is used as a control. GB1, GB1-‚E-som and Ȃ¡Ȃ were all 
at 0.15 mM. 
This is to show how the fusion of ‚E-som ȱ 	ŗȱ ȱ 	ŗȂȱ ǰȱ ȱ  ȱ ȱ
whether GB1 interacts with Ȃ¡Ȃ to see if GB1-‚E-som can be used in future experiments to 
avoid the purification step of the cleavage of ‚E-som from GB1 as this would speed up the 
purification process as well as allowing for a higher yield of ‚E-som as the final product.  
Minimal chemical shift mapping was used to measure the chemical shift change of the 
15N/1H backbone amide peak seen in the HSQC spectra for GB1 on the addition of the fusion 
sequence, or for GB1 and GB1-‚E-som in the presence of Ȃ¡Ȃ. The spectral width of the 15N 
dimension for the amide cross-peaks was 8 times larger than that in the 1H dimensions, so 
the chemical shift change in the 15N dimension was divided by 8 to ensure equal weighting 
in the 1H and 15N dimensions. In minimal chemical shift mapping,  the chemical shift change 
to the nearest peak is measured [105]. This method avoids the need to assign the peaks in the 
second spectrum and gives a minimum value for the magnitude of the chemical change 
assuming that all peaks are still present in the spectrum. 
There was not enough time to run 15N edited TOCSY experiments to unambiguously assign 
GB1 as well as the new cross-peaks in GB1-‚E-som. Assignments for GB1 were made from 
previous data that was found to be in good agreement to our own (Serber, Z., et al., 2006 
[81] 
 
[114] and Sun, Z.Y., et al., 2005 [115]). The backbone amide cross-peaks for ‚E-som were 
labelled as P1 Ȯ P20 as shown in Figure 4.3 B.  The identity of these peaks to residue number 
was unknown. 
2.1 GB1 and GB1-AE-somatostatin 
The assigned HSQC spectrum for GB1 is shown in Figure 4.3 A, and this spectrum is 
shown overlaid with an HSQC spectrum for GB1-‚E-som in Figure 4.3 B. Chemical shift 
changes were measured for all GB1 cross-peaks, and this chemical shift change across the 
sequence of the protein is shown in Figure 4.3 C. Residues 8 Ȯ 12 and 40 Ȯ 44 and 56 of GB1 
showed large shifts, with residue 56 (the C-terminal residue) shifting the most due to it no 





Figure 4.3 HSQC spectra and chemical shift map of GB1 and GB1-AE-somatostatin. 
(A) Assigned HSQC of GB1, (B) GB1 HSQC with GB1-‚E-som HSQC overlaid in blue, with ‚E-som 
cross-peaks marked as P1, P2 etc. (C) chemical shift map showing the chemical shifts that occur 







2.2 GB1 and GB1-AE-sȱ ȱȂ¡Ȃ 
Chemical shift changes seen for GB1 in the absence and presence of Ȃ¡Ȃ are shown in 
Figure 4.5 A. Only very minor shift changes were seen suggesting little or no interaction.  An 
almost identical result was obtained when reduced Ȃ¡Ȃ was added to GB1 (Figure 4.5 C). 
Chemical shift changes of greater magnitude are seen when Ȃ¡Ȃ is added to GB1-‚E-som 
(Figure 4.5 B), ȱ ȱȱ	ŗȱȱȱ‚E-som part of the fusion. The spectra for GB1-‚E-
som and GB1-‚E-som with Ȃ¡Ȃ is given in Figure 4.4 as an example (spectra for chemical 
shift map Figure 4.5 B). In addition to peaks shiftiǰȱ Şȱ ȱ ȱ‚E-som peaks were seen to 
disappear (P7, P8, P9, P11, P15, P16, P18 and P19). A very similar result was seen when 
reduced Ȃ¡Ȃ was added to GB1-‚E-som (Figure 4.5 D), although in this experiment, E56 
was seen to shift considerably less as judged by the closest peak mapping technique. 
Much larger chemical shifts for GB1 and GB1-‚E-som were seen when oxidised Ȃ¡Ȃ was 
added (Figure 4.5 E and F respectively). Interestingly, larger chemical shifts were seen for 
the GB1 portion on the fusion comparȱȱȱ‚E-som section (Figure 4.5 F), however, this 
could be a consequence of the nearest peak analysis which will tend to underestimate 
changes in the crowded central region of the spectrum where the majority of the 
ȱ‚E-som peak were seen (Figure 4.3 B).  A different pattern of behaviours (peaks 
shifting and disappearing) is seen when oxidised Ȃ¡Ȃ ȱ ȱ ȱ ȃȱ Ȅȱ ȱ
reduced Ȃ¡Ȃ (compare Figure 4.5 panels B and D with panel F). This finding suggests a 






   
Figure 4.4 GB1-‚E-som HSQC in blue, and GB1-‚E-som with Ȃ¡Ȃ HSQC overlaid in red. 




Figure 4.5 Chemical shift maps of GB1 (A, C, E) and GB1-AE-somatostatin (B, D, F) 
Blue bars show the residues of GB1 (1-56) and the red bars show the residues for ‚E-som (1-20) 
Asterisks indicate residues whose peaks have become undetectable due to line broadening upon 
addition of Ȃ¡Ȃ. (A) shows GB1 chemical shift changes that occur upon addition of Ȃ¡Ȃ without 
reductant or oxidant, and (B) shows the same but with GB1-‚E-som instead of GB1. (C) shows GB1 
chemical shift changes that occur when reduced Ȃ¡Ȃ (1.5 mM DTT) is added and (D) shows the 
same but with GB1-‚E-som. (E) shows GB1 chemical shift changes that arise when oxidised Ȃ¡Ȃ (5 
mM GSSG) is added to GB1 and (F) shows the same but with GB1-‚E-som. Chemical shift changes 
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3.1 GB1 and GB1-AE-somatostatin 
GB1 presented with chemical shifts spread throughout its structure (Figure 4.3 C). The 
residues localised at the C-terminus shifted the most as shown in Figure 4.6, this was 
because of the close proximity of the fusion sequence. There is only a small possibility that 
the fusion binds to GB1, as there would be much bigger chemical shifts if this had been the 
case. Residue E56 shifted the most (Figure 4.3 C) due to the fusion; this was because E56 was 
no longer the C-terminus, which had a large effect on its environment. 
Figure 4.6 (A) GB1 (pdb structure 2QMT) shown as a backbone cartoon and (B) as a 
surface representation with sidechains in the same orientation and scale. Residues with 
15N/1H backbone amide resonances found not to shift on addition of the C-terminal ‚E-
som fusion sequence are shown in green, those with a chemical shift change >0.06 but 
<0.12 ppm are shown in yellow, whereas those with a chemical shift change >0.12 ppm 
are shown in red. Chemical shift perturbation is seen to be localised and at the end of the 
molecule including the C-terminal residue (E56) as well as the loops between ‚?-strands 1 
















3.2 GB1 and GB1-AE-somatostatin  ȱȂ¡Ȃ 
As the chemical shift changes seen for GB1 with ȃȱȄ Ȃ¡Ȃ and reduced Ȃ¡Ȃ are 
so similar (Figure 4.5 A and C), but different from the result with oxidised Ȃ¡Ȃ (Figure 4.5 
E), it suggests that Ȃ¡Ȃ is purified largely in the reduced form. The same pattern can be 
seen for GB1-‚E-som  ȱȃȱȄȱȱȱȂ¡Ȃ (Figure 4.5 B and D) compared 
to oxidised Ȃ¡Ȃ (Figure 4.5 E).  
It should be noted that the maximum value on the y axis scale in Figure 4.3 C is 0.8 
whereas the y axis of Figure 4.5 A Ȯ F it is 0.1, this shows that there are much greater 
chemical shifts ȱ	ŗȱ ȱ‚E-som is fused to it than when GB1 and GB1-‚E-som interact 
with Ȃ¡Ȃ. 
As the chemical shift perturbations are so small in GB1 with reduced Ȃ¡Ȃ (Figure 4.5 C), 
we can conclude that GB1 does not significantly interact with Ȃ¡Ȃ when it is in the 
reduced form and in the presence of a reductant (1.5 mM DTT), the same can be said for 
when GB1 and Ȃ¡Ȃ are not in the presence of a reductant (Figure 4.5 A). This suggests that 
the chemical shift perturbations seen for GB1-‚E-som in the presence of reduced Ȃ¡Ȃ can 
be attributed to the ‚E-som sequence. This includes those changes in the GB1 portion of 
the fusion ȱ ȱȱȱȱȱ‚E-som sequence.  
GB1 in the presence of oxidised Ȃ¡Ȃ (5 mM GSSG) (Figure 4.5 E) showed a lot more 
chemical shift changes in comparison to reduced Ȃ¡Ȃ (Figure 4.5 C), especially in 
residues Q2, E15, E19 and V21. These residues however are not hydrophobic, and so are 
unlikely to interact with the hydrophobic binding site on the Ȃ domain. This suggests 
that the oxidised environment is having an effect on the GB1 spectrum or that oxidised 
Ȃ¡Ȃ may interact directly with GB1, however this is very unlikely as the residues that 
[88] 
 
shift are not hydrophobic and PDI has a very low affinity for folded proteins. Therefore 
Ȃȱȱ ¢ȱ ȱ ȱ ȱȱ ȱǯ Unfortunately a spectrum of GB1 was 
not collected in the presence of 5 mM GSSG alone which would have determined whether 
the chemical shift changes seen in Figure 4.5 E are due directly to the presence of GSSG. 
In comparison to the chemical shift changes shown in Figure 4.3 C these are relatively 
small, but when comparing these chemical shifts to GB1-‚E-som (Figures 4.5 B, D and F) 
the shifts are significanǲȱȱȱȱȂȱȱaȱȱȱȱȱ‚E-som. 
The ‚E-som peaks that disappeared in Figures 4.5 B, D and F indicate significant interactions 
between ‚E-som and Ȃ¡Ȃ. Therefore weȂȱble to conclude that ‚E-som does interact with 
Ȃ¡Ȃ. 
‚E-som is thought to interact largely via its hydrophobic residues, phenylalanine and 
tryptophan, as previous studies have reported these residues to be important for binding 
[106]. This suggests that four of the disappeared residues in ‚E-som (see Figures 4.5 B, D and 






1.0 Protein expression and purification 
Purification process for PDI fragments is a well-documented protocol and has been 
optimised fully; however nickel affinity chromatography purification of GB1 and GB1-‚E-
som is still to be fully optimised. The concentration of imidazole in the wash buffer could be 
used to see if some of the lower and higher MW bands on the SDS-PAGE analysis become 
fainter or disappear. SDS-PAGE analysis of ¡Ȃ and Ȃ carried out on a non-reducing gel to 
elucidate if the two peaks from ion exchange chromatography are reduced and non-
reduced. 
2.0 Redox potential 
The redox potential of Ȃ still needs to be calculated. This would most likely be achieved 
using a different redox couple other than glutathione or DTT. The redox couples of ‚?-
mercaptoethanol (-260 mV) or lipoic acid (-288 mV) are possible alternatives.  
3.0 Ligand binding 
Confirm backbone assignments for GB1 using a 15N TOCSY experiment to help verify 
sidechain type. Fully assign the HSQC spectrum for GB1-‚E-som using 15N edited TOCSY 
and NOESY experiments to make sequential assignments. This work would allow the 
chemicȱȱȱȱȱȱ‚E-som sequence of the fusion protein to be identified to a 
particular residue. 
It would also be good to determine whether it was oxidised Ȃ¡Ȃ affecting GB1 or the 
oxidising environment itself. To achieve this GB1 would be placed in an oxidising 
environment without Ȃ¡Ȃ or ‚E-som and its chemical shift change measured. 
[90] 
 
Other work could elucidate the Kd value of GB1-‚E-som to reduced or oxidised Ȃ¡Ȃ. A 






Figure 1 Mass spectrometry data for xȂȱȱȱȱ(A) non-reduced and (B) reduced 
forms 
The molecular weight of ¡Ȃ in daltons, in its reduced form is 19267 Da and in its non-
reduced form is 19266 Da. Four additional peaks are shown for the non-reduced and two 
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Figure 2 ȱ¢ȱȱȱȂȱȱ(A) non-reduced and (B) reduced forms 
The molecular weight of Ȃ in daltons, in its reduced form is 17376 Da and in its non-
reduced form is 17376 Da. Two additional peaks are shown for the non-reduced and one 
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